,PageNo,Text
0,page_1,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '1', 'Version Date: 07/22/2019', 'Abbreviated Title: PhII SGI110 in Peds & Adults', 'CC Protocol #: 17-C-0088 B', 'CTEP Protocol #: 10012', 'Version Date: 07/22/2019', 'NCT Number: NCT03165721', 'Title: A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine),', 'in Children and Adults with Wild Type GIST, Pheochromocytoma and Paraganglioma', 'Associated with Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney', 'Cancer', 'Principal Investigator:', 'John Glod, M.D., Ph.D.A-F', 'Pediatric Oncology Branch, CCR, NCI', '10 Center Drive, CRC 1-3940', 'Bethesda, MD 20982', 'Phone: (240) 760-6194', 'Email: john.glod@nih.gov', 'NIH Associate Investigators:', 'Brigitte Widemann, M.D., POB, CCR, NCIA-F', 'Melissa Spencer, R.N., M.S.N., OCD, CCR, NCIA,B,E', 'Joanne Derdak, CRNP, POB, CCR, NCIA,B,E', 'Ram Srinivasan, M.D., UOB, CCR, NCIA-F', 'Marston Linehan, M.D., UOB, CCR, NCIA-F', 'Seth Steinberg Ph.D.. CCR, NCIE,F', 'Lori Wiener, Ph.D., POB, CCR, NCIA,B,E', 'Karel Pacak, M.D., NICHD, NIHA.B,E,F', 'Cody J. Peer, PhD, MS, CCR, NCIE,F', 'William Figg, Pharm.D, CCR, NCIE,F', 'Sima Bedoya, PsyD. POB, CCR, NCIA,B,E', 'Jaydira del Rivero, M.D., OCD, CCR, NCIA-F', 'Paul Meltzer, M.D., GB, CCR, NCI, NIHE,F', 'Donna Bernstein, R.N., OCD, CCR, NCIA,B,E', 'Les R. Folio, DO, MPH, DRD, CC, NIHB,E,F', 'Referral Contact/', 'Study Coordinator:', 'Melissa Spencer, R.N., M.S.N.', 'Office Phone: (240) 760-6101', 'Email: amayamm@mail.nih.go', 'Investigator Roles:', 'A. Obtain information by intervening or interacting with', 'living individuals for research purposes', 'B. Obtaining identifiable private information about living', 'individuals', 'C. Obtaining the voluntary informed consent of', 'individuals to be subjects', 'D. Makes decisions about subject eligibility']"
1,page_2,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '2', 'Version Date: 07/22/2019', 'E. Studying, interpreting, or analyzing identifiable', 'private information or data/specimens for research', 'purposes', 'F. Studying, interpreting, or analyzing coded, linked data', 'or specimens for research purposes', 'G. Some/all research activities performed outside NIH', 'Investigational Agents:', 'Drug Name:', 'SGI-110 (guadecitabine)', 'IND Number:', '133390', 'Sponsor:', 'CTEP', 'Manufacturer:', 'Astex Pharmaceuticals', 'Commercial Agents: None']"
2,page_3,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '3', 'Version Date: 07/22/2019', 'PRÉCIS', 'Background:', 'Loss of activity of the Krebs cycle components succinate dehydrogenase (SDH)', 'complex or fumarate hydratase (FH), has been identified as a mechanism of', 'tumorigenesis in subsets of gastrointestinal stromal tumor (GIST),', 'pheochromocytoma and paraganglioma (PHEO/PGL), and renal cell carcinoma.', 'DNA hypermethylation has been demonstrated in these cancers. Loss of activity of', 'SDH or FH leads to accumulation of the metabolites succinate and fumarate,', 'respectively. Succinate and fumarate act as inhibitors of a broad array of a.-', 'ketoglutarate-dependent dioxygenases. The Ten-eleven Translocation (TET) family', 'of aKG-dependent dioxengenase enzymes convert 5-methylcytosine to 5-', 'hydroxymethycytosine leading to DNA demethylation. Inhibition of these enzymes', 'due to SDH and FH deficiency causes DNA hypermethylation and has been verified', 'in preclinical models.', 'Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of', 'the gastrointestinal tract, resistant to cytotoxic chemotherapy and radiation therapy.', 'KIT and PDGFRA mutations have been identified as tumor initiating events in 85%', 'of adult patients with GIST and these tumors are responsive to the tyrosine kinase', 'inhibitor, Imatinib. In pediatric patients, however, 85% of GISTs lack KIT and', 'PDGFRA mutations (wild-type) and imatinib is not effective.', 'Recent work in the Pediatric and Wild-Type (wt) GIST Clinic at the NCI led to the', 'identification of succinate dehydrogenase (SDH) deficiency in approximately 90% of', 'wild-type GIST¹.', 'In addition to wild-type GIST, SDH deficiency is also present in 30% of', 'pheochromocytoma and paraganglioma (PHEO/PGL) and a subset of renal', 'carcinoma. Loss of SDHB protein expression is seen in PHEO/PGL and wtGIST', 'either due to mutation in SDH subunit genes or hypermethylation of the SDHC', 'promoter region2-4', 'Mutations leading to loss of function of FH have been identified in PHEO/PGL', 'as', 'well as type II papillary renal cell carcinoma in patients with hereditary', 'leiomyomatosis and renal cell cancer (HLRCC)3, An FH-deficient paraganglioma', 'had DNA hypermethylation as demonstrated by array and immunohistochemistr', 'showed increased 5hmC levels in paragangliomas and pheochromocytomas.', 'SGI-110 is a small molecule derivative of decitabine that acts as a DNA', 'methyltransferase (DNMT) inhibitor and is resistant to inactivation by cytidine', 'deaminase, hence may thus have a more favorable pharmacokinetic profile compared', 'to decitabine. Subcutaneously administered SGI-110 is gradually converted to', 'decitabine resulting in prolonged exposure with a several fold increase in apparent', 'T1/2 compared to intravenous decitabine. SGI-110 has been demonstrated in', 'preclinical models to induce a dose-dependent decrease in global DNA methylation', 'and up-regulate expression of specific genes including MAGE-A1 and NY-ESO-1', 'through decreased methylation.', 'We are proposing a phase II trial with SGI-110 in these SDH-deficient and FH-', 'deficient tumors.']"
3,page_4,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '4', 'Version Date: 07/22/2019', 'Objectives:', 'To assess the clinical activity of SGI-110 in patients with wt-GIST, SDH-deficient', 'PHEO/PGL, and HLRCC-associated RCC using RECIST (v1.1).', 'Eligibility:', 'Adults and children (12 years of age) with wt-type GIST, SDH deficient PHEO/PGL,', 'or HLRCC-associated RCC and measurable disease will be eligible.', 'Newly diagnosed patients with PHEO/PGL or HLRCC-associated RCC with localized,', 'resectable disease will not be eligible. Patients with PHEO/PGL or HLRCC-associated', 'RCC with unresectable localized disease and/or metastatic disease will be eligible.', 'Newly diagnosed patients with wt-GIST with completely resectable disease will not be', 'eligible. Patients with wt-GIST with metastatic disease and/or residual or recurrent', 'tumor following surgical debulking will be eligible', 'Patients with wt-GIST or HLRCC-associated RCC who have not previously received', 'systemic therapy are eligible as there are no standard chemotherapy regimens known', 'to be effective for these cancers.', 'Must have adequate performance status, may not be pregnant or breastfeeding, and', 'must have adequate major organ function.', 'No history of severe or uncontrolled inter-current illness including, but not limited to,', 'ongoing or active infection, symptomatic cardiovascular or pulmonary disease will be', 'excluded.', 'Design:', 'This is a single site, open label, phase II study using a small optimal two-stage design', 'to evaluate the clinical response in three groups of patients:', '1. wild-type GIST (GIST without KIT or PDGFRA mutation)', '2. PHEO/PGL in patients with germline SDH subunit mutation, or', '3. RCC associated with HLRCC', 'SGI-110 will be administered subcutaneously at 45mg/m²/day x 5 days on a 28-day', 'cycle to the three groups of patients.', 'SGI-110 activity will be assessed by imaging response of measurable disease using', 'RECISTv1.1, using CT, MRI and/or PET.', 'Patients will be closely monitored for development of toxicity with regular physical', 'examinations and laboratory evaluations. Toxicity will be graded using version 5.0 of', 'the NCI Common Toxicity Criteria.', 'SGI-110 related toxicities > grade 3 will be considered treatment limiting toxicities,', 'unless they are reversible within 72 hours with supportive care. Following recovery', 'from toxicity up to 2 dose reductions will be allowed.', 'Initially 7 evaluable patients in each group (strata) will be enrolled and if 0 of the 7', 'have a response, then no further patients will be accrued in that strata. If 1 or more the', 'first 7 (14.3% or more) have a response, then accrual would continue until a total of 21', 'patients have enrolled in that strata. If at least 3 responses (at least 14.3%) are observed', 'among the 21 evaluable patients, the agent should be considered worthy of further', 'testing in this disease.']"
4,page_5,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '5', 'Version Date: 07/22/2019', 'Enrolling 2 patients/month, it is estimated to require 3 years to complete accrual to a', 'maximum of 70 patients, a maximum of 63 evaluable patients allowing for a small', 'number (7) of inevaluable patients.']"
5,page_6,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '6', 'Version Date: 07/22/2019', 'TABLE OF CONTENTS', 'PRÉCIS', '3', 'TABLE OF CONTENTS', '6', '1', 'INTRODUCTION', '12', '1.1', 'Study Objectives', '12', '1.1.1', 'Primary Objective', '12', '1.1.2', 'Secondary', '12', '1.1.3', 'Exploratory', '12', '2', 'BACKGROUND AND RATIONALE', '12', '2.1.1', 'Background', '12', '2.1.2', 'Gastrointestinal stromal tumors', '12', '2.1.3', 'Pheochromocytoma and Paraganglioma', '13', '2.1.4', 'Renal Cell Carcinoma', '13', '2.1.5', 'SGI-110', '13', '2.1.6', 'Health-Related Quality of Life and Patient-Reported Symptoms', '15', '2.1.7', 'Rationa le', '16', '3', 'PATIENT SELECTION', '16', '3.1', 'Eligibility Criteria', '16', '3.1.1', 'Inclusion Criteria:', '16', '3.1.2', 'Exclusion Criteria', '18', '4', 'RECRUITMENT AND REGISTRATION', '19', '4.1 Recruitment', '19', '4.2', 'Screening Evaluation', '19', '4.2.1', 'History and physical examination', '19', '4.2.2', 'Imaging evaluation', '19', '4.2.3', 'Hematology', '19', '4.2.4', 'Chemistries', '20', '4.2.5', 'Urine or serum pregnancy test for all females of childbearing potential', '20', '4.2.6', 'Pathologic/Tissue Evaluation', '20', '4.2.7', 'For patients with PHEO/PGL', '20', '4.3', 'Registration Procedures', '20', '4.3.1', 'IWRS', '20', '4.3.2', 'OPEN/IWRS', '20', '4.3.3', 'OPEN/IWRS User Requirements', '21', '4.3.4', 'OPEN/IWRS Questions?', '21']"
6,page_7,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '7', 'Version Date: 07/22/2019', '4.4', 'Local Registration for NCI CCR', '21', '5', 'STUDY IMPLEMENTATION', '21', '5.1', 'Study Design', '21', '5.2', 'Drug Administration', '22', '5.3', 'Dose Modifications', '22', '5.4', 'Questionnaires (Appendix III and Appendix IV)', '23', '5.4.1', 'PROMIS', '23', '5.4.2', 'Distress Rating Tool', '23', '5.5', 'On-Study Evaluation', '23', '5.5.1', 'Baseline Assessment', '23', '5.6', 'Study Calendar', '24', '5.7', 'Criteria for Removal from Protocol Therapy and Off Study Criteria', '27', '5.7.1', 'Criteria for removal from protocol therapy', '27', '5.7.2', 'Off-Study Criteria', '27', '5.7.3', 'Off Protocol Therapy and Off-Study Procedure', '27', '6', 'CONCOMITANT MEDICATIONS/MEASURES', '27', '6.1', 'Injection Site Reactions', '27', '6.2 Mucositis', '28', '6.3', 'Diarrhea', '28', '7', 'BIOSPECIMEN COLLECTION', '28', '7.1', 'Correlative Studies for Research/Pharmacokinetic Studies', '28', '7.1.1', 'Pharmacokinetics', '28', '7.1.2', 'Expression of SDH complex subunits and FH', '29', '7.1.3', 'DNA hyper-methylation', '29', '7.1.4', 'NY-ESO-1 expression', '29', '7.1.5', 'Serum and Urine Concentrations of glycolytic metabolites', '29', '7.2', 'Sample Storage, Tracking and Disposition', '31', '7.2.1', 'Sample Storage and Destruction', '31', '8', 'MEASUREMENT OF EFFECT', '32', '8.1', 'Definitions', '32', '8.2', 'Disease Parameters', '33', '8.2.1', 'Methods for Evaluation of Measurable Disease', '34', '8.2.2', 'Response Criteria', '36', '8.2.3', 'Duration of Response', '37', '9', 'ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS', '38']"
7,page_8,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '8', 'Version Date: 07/22/2019', '9.1', 'Comprehensive Adverse Event and Potential Risk List (CAEPRs)', '38', '9.1.1', 'Comprehensive Adverse Events and Potential Risks list (CAEPR for SGI-110', '(NSC 780463)', '38', '9.2', 'Adverse Event Characteristics', '42', '9.3', 'Expedited Adverse Event Reporting to CTEP', '42', '9.3.1', 'Expedited AE reporting', '42', '9.3.2', 'Distribution of Adverse Event Reports', '43', '9.3.3', 'Expedited Reporting Guide lines', '43', '9.4', 'Routine Adverse Event Reporting to CTEP', '44', '9.5', 'Secondary Malignancy', '44', '9.6', 'Second Malignancy', '45', '10 NIH Intramural Research Program Reporting', '45', '10.1', 'Definitions', '45', '10.2', 'OHSRP Office of Compliance and Training/ IRB Reporting', '45', '10.2.1', 'Expedited Reporting', '45', '10.2.2', 'IRB Requirements for PI Reporting at Continuing Review', '45', '10.3', 'NCI Clinical Director Reporting', '45', '11', 'STUDY OVERSIGHT AND DATA REPORTING/REGULATORY REQUIREMENTS', '45', '11.1', 'Study Oversight', '45', '11.2', 'Data Reporting', '46', '11.2.1', 'Method', '46', '11.3', 'Data Sharing Plans', '47', '11.3.1', 'Human Data Sharing Plan', '47', '11.3.2', 'Genomic Data Sharing Plan', '47', '12', 'STATISTICAL CONSIDERATIONS', '47', '13 COLLABORATIVE AGREEMENTS', '48', '14 HUMAN SUBJECTS PROTECTIONS', '49', '14.1', 'Rationale For Subject Selection', '49', '14.1.1 Gender and Minority Accrual Estimates', '49', '14.2', 'Participation of Children', '50', '14.3', 'Participation of Subjects Unable to Give Consent', '50', '14.4', 'Evaluation of Benefits and Risks/Discomforts', '51', '14.4.1', 'Risks of SGI-110', '51', '14.5', 'Risks/Benefits Analysis', '51']"
8,page_9,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '9', 'Version Date: 07/22/2019', '14.6', 'Consent and Assent Process and Documentation', '51', '14.6.1', 'Consent for minors when they reach the age of majority', '52', '14.6.2', 'Telephone consent', '53', '15 PHARMACEUTICAL INFORMATION', '53', '15.1 SGI-110 (Guadecitabine) (NSC 780463)', '53', '15.1.1 Agent Ordering and Agent Accountability', '55', '15.1.2 Incompatibilities', '56', '16 APPENDICES', '57', '16.1', 'Appendix I-Performance Status Criteria', '57', '16.2', 'Appendix II: Performance Status Scales/Scores in Patients 16 years of age', '58', '16.3', 'Appendix III: Quality of Life Tools', '59', '16.3.1', 'Pediatric PROMIS Instruments English (6)', '59']"
9,page_10,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '10', 'Version Date: 07/22/2019', '16.3.2', 'Pediatric PROMIS Instruments Spanish (6)', 'PROMIS Pediatric v.1.1 - Depressive Symptoms - Short Form 8b', 'Síntomas de depresión en pediatría - Cuestionario abreviado 8b', 'Responde a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Nunca', 'Casi nunca', 'A veces', 'A menudo', 'Casi siempre', 'No pude dejar de', 'sentirme triste.', '0', '1', '2', '3', '4', '4B1R1', 'Senti que estaba solo/a.', '0', '1', '2', '3', '4', '5041R1', 'Senti que todo me salía', 'mal en la vida.', '0', '1', '2', '3', '4', '5035R1', 'Senti que no podía hacer', 'nada bien.', '0', '1', '2', '3', '4', '711R1', 'Me senti solo/a.', '0', '1', '2', '3', '4', '226R1', 'Me senti triste.', '0', '1', '2', '3', '4', '71281', 'Me senti descontento/a.', '0', '1', '2', '3', '4', 'Me resultó difícil', 'divertirme.', '0', '1', '2', '3', '4', 'Spanish (Universal)', '27 January 2014', 'c 2009-2013 PROMIS Health Organization and PROMIS Cooperative Group', '65', '16.3.3', 'Paralle 1 Parent Proxy PROMIS Instruments English (6)', '71', '16.3.4', 'Adult Patient PROMIS Instruments English (6)', '77']"
10,page_11,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '11', 'Version Date: 07/22/2019', '16.3.5 Adult Patient PROMIS Instruments Spanish (6)', 'PROMIS Item Bank V. 1.2 - Physical Function - Short Form 10a', 'Capacidad de funcionamiento físico - Cuestionario abreviado 10a', 'Responda a cada pregunta marcando una casilla por línea.', 'No puedo', 'Nada', 'Poco', 'Algo', 'Mucho', 'hacerlo', '¿Limita su salud en este momento su capacidad', 'PFA1', 'para realizar actividades vigorosas, como correr,', '5', '4', '3', '2', '1', 'levantar objetos pesados o participar en deportes', 'enérgicos?', 'Limita su salud en este momento su capacidad', 'PFC36r1', 'para caminar más de una milla (1.6 km)?', '5', '4', '3', '2', '1', 'PFC37', '¿Limita su salud en este momento su capacidad', 'para subir un piso de escaleras?', '5', '4', '3', '2', '1', '¡Limita su salud en este momento su capacidad', 'PFAS', 'para levantar o llevar las bolsas del', '5', '4', '3', '2', '1', 'supermercado?', '¿Limita su salud en este momento su capacidad', 'PFA3', 'para inclinarse, arrodillarse o agacharse?', '5', '4', '3', '2', '1', 'Con', 'Con', 'Sin', 'Con poca', 'alguna', 'mucha', 'No puedo', 'dificultad', 'dificultad', 'dificultad', 'dificultad', 'hacerlo', 'PFA11', '¿Puede realizar tareas, como pasar la aspiradora', '5', '4', '3', '2', '1', 'o trabajar en el jardin?', 'PFA16r1', '¿Puede vestirse sin ayuda, incluso amarrarse los', '5', '4', '3', '2', '1', 'zapatos y abotonarse la ropa?', 'PFB26', '¿Puede lavarse el cabello con champú?', '5', '3', '2', '1', 'PFA55', '¿Puede lavarse y secarse el cuerpo?', '5', '4', '3', '2', '1', 'PFC45r1', '¿Puede sentarse y levantarse del inodoro', '(excusado)?', '5', '4', '3', '2', '1', 'Spanish (Universal)', '21 January 2014', '© 2008-2013 PROMIS Health Organization and PROMIS Cooperative Group', 'Page of 1', '84', '16.4', 'Appendix IV: The Distress and Symptom Checklist: The Distress Thermometer 90', '17 REFERENCES', '92']"
11,page_12,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '12', 'Version Date: 07/22/2019', '1', 'INTRODUCTION', '1.1', 'STUDY OBJECTIVES', '1.1.1 Primary Objective', 'To assess the clinical activity (CR or PR) of SGI-110 in patients with wt-GIST, SDH-', 'deficient PHEO/PGL, and HLRCC-associated renal cell carcinoma using RECIST (v1.1).', '1.1.2 Secondary', '1.1.2.1 Evaluate the toxicity, progression-free (PFS) and overall survival (OS), and pain and', 'quality of life (QOL) of patients on treatment with SGI-110.', '1.1.2.2', 'Better define the pharmacokinetics (PK) of SGI-110 in all patients.', '1.1.3', 'Exploratory', '1.1.3.1', 'Determine the serum and urine concentration of succinate, fumarate and 2-', 'hydroxyglutarate in patients with wild-type GIST, pheochromocytoma and', 'paraganglioma associated with SDH deficiency and HLRCC-associated kidney', 'cancer prior to and on therapy with SGI-110.', '1.1.3.2', 'Explore changes in DNA methylation and gene expression including SDH, FH, and', 'tumor testis antigens in response to treatment with SGI-110.', '1.1.3.3 Assess the global DNA methylation status in tumors by determining LINE-1', 'methylation in archival pre-treatment tumor samples and in on-treatment tumor', 'samples when available.', '2', 'BACKGROUND AND RATIONALE', '2.1.1 Background', 'Loss of activity of the Krebs cycle components succinate dehydrogenase (SDH) complex or', 'fumarate hydratase (FH), has been identified as a mechanism of tumorigenesis in subsets of', 'gastrointestinal stromal tumor (GIST), pheochromocytoma and paraganglioma (PHEO/PGL),', 'and renal cell carcinoma.', 'DNA hyper-methylation has been demonstrated in these cancers 2,6,7 Loss of activity of SDH', 'or FH leads to accumulation of the metabolites succinate and fumarate, respectively.', 'Succinate and fumarate act as inhibitors of a broad array of a-ketoglutarate-dependent', 'dioxygenases. The Ten-eleven Translocation (TET) family of dioxengenase', 'enzymes convert 5-methylcytosine to 5-hydroxymethycytosine leading to DNA', 'demethylation. Inhibition of these enzymes due to SDH and FH deficiency causes DNA', 'hypermethylation8. It is hypothesized that a methylation inhibitor would impact tumor growth', 'by reversing the DNA hypermethylation that is seen in this group of tumors with Krebs cycle', 'abnormalities.', '2.1.2 Gastrointestinal stromal tumors', 'Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the', 'gastrointestinal tract, resistant to cytotoxic chemotherapy and radiation therapy. KIT and', 'PDGFRA mutations have been identified as tumor initiating events in 85% of adult patients', 'with GIST and these tumors are responsive to the tyrosine kinase inhibitor, Imatinib9. In', 'pediatric patients, however, 85% of GISTs lack KIT and PDGFRA mutations (wild-type']"
12,page_13,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '13', 'Version Date: 07/22/2019', 'GIST)10 and imatinib is not effective. Recent work in the Pediatric and Wild-Type (wt) GIST', 'Clinic at the NCI led to the identification of succinate dehydrogenase (SDH) deficiency in', '88% of pediatric wild-type GIST1,10 Loss of SDHB protein expression is seen in PHEO/PGL', 'and wt-GIST either due to mutation in SDH subunit genes or hypermethylation of the SDHC', 'promoter region, which was seen in 21 of 95 wild-type GIST tumors examined1,10', '2.1.3 Pheochromocytoma and Paraganglioma', 'In addition to wild-type GIST, SDH deficiency is also present in pheochromocytoma and', 'paraganglioma (PHEO/PGL)3,11 Pheochromocytomas (PHEOs) and paragangliomas (PGLs)', 'are neuroendocrine tumors arising from the adrenal chromaffin cells and ganglia along the', 'sympathetic and parasympathetic chains, respectively. Seventeen underlying germline', 'mutations associated with PHEO/PGL have been identified and account for approximately', '35% of PHEO/PGL12 Approximately 10-30% of PHEO/PGL are SDH-deficient13,14 and', 'there is an increased risk of more aggressive metastatic disease in patients with SDHB', 'mutation. SDHC promoter hypermethyation has also been described in PHEO/PGL as', 'mechanisms for SDH deficiency in isolated paraganglioma15 as well as in patients with', 'Carney Triad16 However, the percentage of SDH deficient PHEO/PGL with SDHC promoter', 'hypermethylation is unknown. Surgical resection is the only curative therapy for patients with', 'PHEO/PGL, however both radiation therapy and cytotoxic chemotherapy using', 'cyclophosphamide, vincristine, and dacarbazine (CVD) have been used to treat patients with', 'metastatic or recurrent disease 12 Averbuch and colleagues reported a 57% response rate in', 'pateints with malignant pheochromocytomal7. A recent retrospective analysis of 17 patients', 'with metastatic PHEO/PGL showed a 47.1% rate of response to CVD18 A meta-analysis of', 'patients with metastatic PHEO/PGL treated with CVD chemotherapy showed a 4% CR and', '37% PR rate19 Approximately 60% of metastatic PHEO/PGL are methyl-iodobenzylguanine', '(MIBG) avid and can be treated with 131I-MIBG20. A meta-analysis of patients treated with', '131I-MIBG showed a complete response rate of 3% and PR rate of 27%21. A small number', 'of patients with metastatic PHEO/PGL have also been reported to have disease response', 'when treated with temozolomide. While CVD chemotherapy has been described as standard', 'therapy for PHEO/PGL20 the data supporting this therapeutic approach is limited. 131I-MIBG', 'in patients with MIBG avid tumors or cytotoxic chemotherapy (CVD or temozolomide) is', 'required prior to enrollment on this trial. However, patients who have refused cytotoxic', 'chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic', 'chemotherapy is felt to be in the best interest for the patient by the local investigator will also', 'be eligible.', '2.1.4 Renal Cell Carcinoma', 'Mutations leading to loss of function of FH have been identified in type II papillary renal cell', 'carcinoma in addition to PHEO/PGL6. Hereditary leiomyomatosis and renal cell carcinoma', '(HLRCC) is an autosomal-dominant hereditary syndrome due to mutations in FH5.', 'Approximately 93% of patients with HLRCC have detectable mutations in FH4. While renal', 'cell cancer occurs less often than leiomyomas in patients with HLRCC, HLRCC-associated', 'kidney cancer is typically clinically aggressive with early development of metastatic disease.', 'Nephron-sparing surgical therapy is standard for localized HLRCC-associated renal cancer22.', 'While there is currently no standard systemic therapy for metastatic HLRCC-associated renal', 'cell cancer, treatments targeting the VEGF and EGFR pathways are being investigated in', 'ongoing clinical trials22.', '2.1.5 SGI-110']"
13,page_14,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '14', 'Version Date: 07/22/2019', 'SGI-110 is a small molecule derivative of decitabine that acts as a DNA methyltransferase', '(DNMT) inhibitor and is resistant to inactivation by cytidine deaminase23 Subcutaneously', 'administered SGI-110 is gradually converted to decitabine resulting in prolonged exposure', 'with a several fold increase in apparent T1/2 compared to intravenous decitabine. SGI-110 has', 'been demonstrated in preclinical models to induce a dose-dependent decrease in global DNA', 'methylation and up-regulate expression of specific genes including MAGE-A1 and NY-ESO-', '1 through decreased methylation.', '2.1.5.1 Pharmacokinetics of SGI-110', 'Studies were conducted in mice, rats, monkeys and rabbits to examine the PK profile of SGI-', '110 available as a sodium salt. Intravenous, bolus, oral, and SC routes of administration were', ""evaluated. Results of these studies are available in the Investigator's Brochure"", ""(Guadecitabine: Investigator's Brochure. Version 6.0, 10September 2015). In summary, in"", 'vivo oral bioavailability in rodents was greater than 30%, but in vitro permeability measured', 'in human Caco-2-cells was poor. Additionally, SGI-110 degrades rapidly both chemically', 'due to hydrolysis and enzymatically due to presence of phosphodiesterases and other', 'enzymes (phosphatases, phosphorylases, etc.). These findings substantiate the selection of a', 'parenteral route for dosing. Comparative studies indicate close to 100% bioavailability via', 'subcutaneous (SC) administration. Once in the biological system, SGI-110 cleaves to', 'decitabine, a known active moiety. The rate of this conversion to decitabine varies across', 'species and appears to be much higher in rats and rabbits, compared to primates. When', 'administered SC to non-human primates, SGI-110 releases decitabine slowly compared to', 'other species, possibly prolonging the effect over more sustained periods. Therefore, SC', 'route of administration is recommended.', 'The recommended safe starting dose of SGI-110 for human studies, [Regimen 1 (Daily x5): 3', 'mg/m²/dose, and Regimen 2A (Weekly X3) 6 mg/m²/dose], was based on (1) results from', 'repeat-dose toxicology studies in rabbits (the most sensitive species) and rats; (2) results from', 'a non-GLP non-human primate toxicology, PD and TK study; (3) the established PK and', 'safety profile for decitabine.', '2.1.5.2 Clinical Studies in Humans', 'As of 30 June 2015, 5 clinical trials of SGI-110 have been initiated: 3 as monotherapy in', 'AML/MDS, 1 as monotherapy in HCC and 1 in combination with carboplatin in ovarian', 'cancer. Three dosing regimens (Daily X 5, Once weekly, and twice weekly) were employed', 'in the initial phase I study in adult patients with high-risk myelodysplastic syndrome (MDS)', 'or acute myelogenous leukemia (AML). In a subsequent Phase 2 study doses of', '60mg/m²/day Daily x5 and 90mg/m²/day Daily x5 were used in subjects with MDS or AML.', 'An additional cohort in this study was treated with 60mg/m²/day for 10 days.', 'In a single agent study, the maximum tolerated dose of the drug for the first cycle when given', 'Daily X 5 to patients with MDS was 90mg/m²/dose. Dose limiting toxicities seen at', '125mg/m²/day in this patient population were thrombocytopenia, neutropenia, febrile', 'neutropenia, and sepsis. The MTD was not reached for patients with AML with the highest', 'dose administered 125mg/m²/day Daily x5. In a phase II dose expansion for patients with', 'AML and MDS dosing regimens of 60mg/m²/day Daily x5 and 90 mg/m2/day Daily x5 have', 'been used. A total of 202 subjects have been treated using these regimens. There were no', 'significant differences in complete response rates between 60mg/m²/day Daily x5 and 90', 'mg/m²/day Daily x5 in relapsed/refractory AML subjects (13% VS 19% respectively) or in', 'treatment naïve elderly subjects with AML (54% VS 55%, respectively). The biologically', 'effective dose was determined by assaying LINE-1 demethylation. In these patients there']"
14,page_15,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '15', 'Version Date: 07/22/2019', 'was also no significant difference in LINE-1 demethylation between patients treated on the', 'two different dosing regimens. A smaller number of patients with AML and MDS have been', 'treated using a schedule of 10 days of treatment per cycle (days 1-5 and days 8-12).', 'Patients with platinum-resistant ovarian cancer were enrolled on a phase II combination trial', 'of SGI-110 and carboplatin (NCT01696032). In combination with carboplatin a starting dose', 'of SGI-110 of 45mg/m²/day Daily x5 was not tolerated and the dose was de-escalated to', '30mg/m²/day. Dose of SGI-110 of 30mg/m²/day + carboplatin AUC 4 was well-tolerated', 'and is being used for stage II of the study. In patients with HCC, a Phase II study of mono-', 'therapy with SGI-110 is ongoing (NCT01752933). Dosing started at 60mg/m²/day on days', '1-5 every 28 days. This dose was reduced to 45mg/m²/day Daily x5 due to grade >/=3', 'hematological toxicity. Thirty-six subjects received this dose on stage 2 of this study.', 'Overall, 22 of 50 subjects (44%) had SAEs in this study. Most subjects had SAEs considered', 'not related to study treatment. No SAE with an outcome of death was considered related to', 'study treatment.', '2.1.6 Health-Related Quality of Life and Patient-Reported Symptoms', '2.1.6.1 Study Measures', 'Distress and Symptom Checklist (Appendix IV): The Distress Thermometer 24 is a brief', 'screening tool endorsed by the National Comprehensive Cancer Network (NCCN) to assess', 'for distress in adult cancer patients. The Distress Thermometer (DT) is a visual-analog scale', 'similar to those used to assess pain. The DT obtains an overall distress score based on the', 'visual analog scale, and includes a ""problem list"", or checklist, where patients can identify', 'specific physical and emotional symptoms and practical and family concerns that can cause', 'their distress. The DT has been widely validated in adult (18 years old) cancer patients, and', 'has been recognized as a good alternative to many of the longer measures commonly used to', 'screen for distress in cancer patients 25-27', 'Whereas the Distress Thermometer was originally written for adult cancer patients, early', 'evaluation of the scale shows validity for children and adolescents with cancer 28 In an', 'ongoing study at the NIH with 163 pediatric patients ages 7-21 undergoing treatment for', 'cancer, NF1, HIV or a primary immune deficiency and their caregivers, an adapted DT has', 'shown convergent validity when compared with standardized measures and with specific', 'items on the symptom checklist. It has also shown reasonable concordance with parent and', 'provider ratings 29. For this study, we will use the DT as a distress and symptom rating tool. It', 'is quick to administer and a low burden to patients and their caregivers 29 Whereas most', 'patient reported outcome measures utilize a 7-day recall period (including the PROMIS', 'measures), the adapted DT utilizes a 30 day recall period which allows problems or', 'symptoms that might have been present in the past month, but not necessarily the past week', 'to be documented. The distress and symptom rating scales will take approximately 5 minutes', 'to complete.', 'Patient-Reported Outcomes Measurement Information System (PROMIS) is a health related', 'quality of life measurement tool that was developed by NIH to standardize patient-reported', 'outcomes for national use by research clinicians. Two versions of PROMIS are available to', 'researchers: computer-adaptive tests (CATs) and short forms. The short forms are brief, static', 'instruments that have demonstrated similar reliability to the longer, dynamic CATs, which', 'provide precise measures for studying populations with widely varied responses and', 'longitudinal self-report data 30. Each short form includes 4 to 8 items, measures reported', 'health outcomes in the past 7 days on a Likert type scale, and takes approximately 5 minutes']"
15,page_16,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '16', 'Version Date: 07/22/2019', 'to complete. PROMIS instruments, measuring a broad range of health domains, have been', 'validated for adults (18) with a variety of health conditions 31.', 'Early evaluation of PROMIS pediatric instruments indicates validity for children ages 8 to 17', '32, hence this is appropriate for the age group 12-17 years old in this trial. Six pediatric', 'PROMIS instruments and six parallel Parent Proxy PROMIS instruments (See Appendix III)', 'are available to assess five quality of life health domains (physical function, pain', 'interference, fatigue, emotional health, and social health) and are intended for use with both', 'healthy and chronically ill pediatric populations. This protocol will utilize pediatric PROMIS', 'short forms and the Parent Proxy short forms to assess symptoms that can be associated with', 'GIST. These include physical function, anxiety, depressive symptoms, fatigue, pain', 'interference, and peer relationships.', 'Assessments of Health-Related Quality of Life will be administered at the start of therapy, at', 'the end of cycle 4 and then every 4 cycles thereafter, and then at the end of therapy. The', 'PROMIS Patient Outcome Measures (6) and patient-reported symptom severity (Distress and', 'Symptom Checklist) will provide us with essential information regarding how symptoms may', 'change over the course of treatment, and will also provide a more in-depth assessment of the', 'known toxicities associated with SGI-110 in this patient population.', 'The PI of the study will be notified of participants who have scores 2 standard deviations', 'above the mean normative t-score of 50 (so a t-score of 70) on the PROMIS depression short', 'form (suggesting high depression), and these participants will be assessed for suicidal', 'ideation by a member of the psychosocial team. Those found to have suicidal ideation will be', 'referred to the NIH psychiatry service.', '2.1.7 Rationale', 'Based on the dosing regimens that have been tolerated in these ongoing trials we propose a', 'starting dose for single agent therapy of 45mg/m²/day daily x5 on a 28 day cycle. The', 'majority of patients enrolled on our trial will not have had extensive therapy with cytotoxic', 'agents and hence would not be expected to experience the degree of bone marrow toxicity', 'that was observed in patients on these earlier trials. Because GIST, RCC, and PHEO/PGL', 'are more indolent tumors it may be expected that a more prolonged course of treatment will', 'be given to our patients. In order to facilitate more long-term dosing of the drug two dose de-', 'escalations of approximately 30% will be allowed.', '3', 'PATIENT SELECTION', '3.1', 'ELIGIBILITY CRITERIA', '3.1.1 Inclusion Criteria:', 'Patients must:', '3.1.1.1 Have recurrent or refractory/unresectable disease for which there is no known', 'curative therapy.', 'Wild type-GIST: Patients with recurrent or progressive disease will be eligible.', 'Newly diagnosed patients with resectable localized disease will not be eligible. Newly', 'diagnosed patients with metastatic disease and newly diagnosed patients with residual', 'tumor following surgical debulking will be eligible.']"
16,page_17,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '17', 'Version Date: 07/22/2019', 'PHEO/PGL: Patients with recurrent or progressive disease will be eligible. Newly', 'diagnosed patients with PHEO/PGL that is metastatic at diagnosis and/or unresectable', 'will be eligible Patients with PHEO/PGL with localized (non-metastatic), resectable', 'disease will not be eligible.', 'Renal cell cancer associated with HLRCC: Patients with localized, resectable', 'HLRCC-associated renal cell cancer will not be eligible. Patients with metastatic', 'and/or unresectable HLRCC-associated renal cell cancer will be eligible.', '3.1.1.2 Have one of the following confirmed histologically, cytologically, or through', 'biochemical testing:', 'wild-type GIST (GIST without KIT or PDGFRA mutation);', 'PHEO/PGL with a germline mutation in SDHA, SDHB, SDHC, or SDHD;', 'renal cell cancer associated with HLRCC.', 'Testing will be performed in CLIA certified labs using genetic tests for KIT/PDGFRA', 'and testing panels developed for patients with PHEO/PGL. Results from outside labs will', 'be accepted. Pathologic diagnosis will be reviewed and verified at the Clinical Center.', '3.1.1.3 Age: be > 12 years of age', 'Because there is no dosing or adverse event data currently available on the use of SGI-110 in', 'children < 18 year of age, children < 12 years of age will be excluded from this study, but', 'may be eligible for future pediatric trials should the results of the study be positive.', '3.1.1.4 Measurable disease:', 'Have measurable disease, defined as at least one lesion that can be accurately measured in at', 'least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for', 'nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.', 'See Section 8.2.2 for the evaluation of measurable disease (RECIST v1.1).', '3.1.1.5 Prior Therapy', '3.1.1.5. 1 Prior therapy requirements:', 'Wt-GIST: Because there are no standard chemotherapy regimens known to be', 'effective for wt-GIST, previously untreated participants are eligible.', 'PHEO/PGL with germline SDH subunit mutation: 131I-MIBG in patients with MIBG', 'avid tumors or cytotoxic chemotherapy (CVD or temozolomide) is required prior to', 'enrollment on this trial. However, patients who have refused cytotoxic chemotherapy', 'or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is', 'felt to be in the best interest for the patient by the local investigator will also be', 'eligible.', 'HLRCC-associated renal cell cancer: Because there are no standard chemotherapy', 'regimens known to be effective for HLRCC-associated renal cell cancer, previously', 'untreated participants are eligible.', '3.1.1.5.2Prior therapy wash-out period requirements', 'Participants must be at least 4 weeks from prior surgical procedures and surgical', 'incisions must be healed.']"
17,page_18,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '18', 'Version Date: 07/22/2019', 'Participants must have had their last fraction of external beam radiation therapy at', 'least 4 weeks prior to enrollment. Participants with prior radiation therapy must be at', 'least 4 weeks post therapy and have had progression of disease outside the radiation', 'port.', 'Participants must have had their last dose of cytotoxic chemotherapy at least 28 days', 'prior to enrollment, their last dose of biological therapy, such as biological response', 'modifiers (e.g., cytokines), immunomodulatory agents, vaccines, differentiating', 'agents, used to treat their cancer at least 28 days prior to enrollment, their last dose of', 'a monoclonal antibody at least 28 days prior to enrollment, and their last dose of any', 'investigational agent at least 28 days prior to enrollment.', 'Participants must have recovered from the acute toxic effects of prior therapy to a', 'grade 1 (CTCAE v.5.0) level prior to enrollment (does not apply to alopecia).', '3.1.1.6 Performance Level: ECOG performance status <2 or Karnofsky >60% in patients', '>', '16 years of age, Lansky > 60 for patients VI 16 years of age (See Appendix I).', '3.1.1.7 Have normal organ and marrow function as defined below:', '- absolute neutrophil count', '>1,500/mcL', '- platelets', '>100,000/mcL', '- total bilirubin', 'within normal institutional limits', '- AST(SGOT)/ALT(SGPT)', '<2.5 X institutional upper limit of', 'normal', '- creatinine', 'within normal institutional limits', 'OR', '- creatinine clearance', '>60 mL/min/1.73 m² for patients with', 'creatinine levels above institutional', 'normal.', '3.1.1.8 Birth Control:', 'The effects of SGI-110 on the developing human fetus are unknown. For this reason and', 'because decitabine is known to be teratogenic, women of child-bearing potential and men must', 'agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)', 'prior to study entry and for the duration of study participation, and for 6 months following', 'participation. Should a woman become pregnant or suspect she is pregnant while she or her', 'partner is participating in this study, she should inform her treating physician immediately.', '3.1.1.9 Ability of subject or legal guardians (if the patient is <18 years old) to understand', 'and the willingness to sign a written informed consent document.', '3.1.2 Exclusion Criteria', 'Patients with any one the following will be excluded:', '3.1.2.1 Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor,', 'immunotherapy, or biologic therapy, including investigational agents for their', 'disease.', '3.1.2.2 History of allergic reactions to SGI-110 or decitabine.', '3.1.2.3', 'Uncontrolled intercurrent illness including, but not limited to, symptomatic', 'congestive heart failure, unstable angina pectoris, cardiac arrhythmia, symptomatic']"
18,page_19,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '19', 'Version Date: 07/22/2019', 'pulmonary disease or psychiatric illness/social situations that would limit', 'compliance with study requirements.', '3.1.2.4 Pregnant or breastfeeding', 'Pregnant women are excluded from this study because SGI-110 is a derivative of decitabine', 'which has the potential for teratogenic or abortifacient effects. Because there is an unknown', 'but potential risk for adverse events in nursing infants secondary to treatment of the mother', 'with SGI-110, breastfeeding should be discontinued if the mother is treated with SGI-110.', 'These potential risks may also apply to other agents used in this study.', '3.1.2.5 Any evidence of severe or uncontrolled systemic disease, active infection, active', 'bleeding diatheses, or renal transplant, including any patient known to have hepatitis', 'B, hepatitis C, or human immunodeficiency virus (HIV) will be excluded. Patients', 'with HIV who have adequate CD4 count, not requiring antiretroviral medication,', 'may be enrolled.', '3.1.2.6 Patients who, in the opinion of the investigator, may not be able to comply with the', 'safety monitoring requirements of the study.', '4', 'RECRUITMENT AND REGISTRATION', '4.1 RECRUITMENT', 'In addition to posting this study on clinicaltria ls.gov and the NCI website, patients who may', 'be eligible will be invited to undergo screening during their participation in CCR Clinical', 'studies, i.e. GIST Clinic held by POB, and RCC Clinic held by UOB, and PHEO/PGL Clinic', 'held by NICHD.', '4.2 SCREENING EVALUATION', 'Eligibility will be determined during a pre-study evaluation period after subjects have signed', 'a consent (either a screening consent or this treatment consent). Subject information must be', 'entered onto a screening log and for subjects not registered (enrolled) on the treatment', 'portion of the study, a brief reason will be entered onto the screening log.', 'Screening blood tests should be performed within 72 hours and imaging studies within 4', 'weeks prior to enrollment on the trial unless otherwise stated. Any abnormal laboratory', 'result that might preclude eligibility can be repeated within 24 hours.', '4.2.1 History and physical examination', 'Complete history, including prior and concurrent therapy; physical examination', 'including documentation of measurable disease, performance status, blood pressure,', 'height, weight, signs and symptoms.', '4.2.2', 'Imaging evaluation', 'Assessment of measurable disease sites by appropriate radiological evaluation. This', 'may include a CT scan of chest, abdomen and pelvis and primary tumor, MRI scan of', 'primary tumor and FDG-PET scan, as clinically indicated.', '4.2.3', 'Hematology', 'Complete blood count with differential and platelets.']"
19,page_20,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '20', 'Version Date: 07/22/2019', '4.2.4 Chemistries', 'Electrolytes (including sodium, potassium, chloride, CO2), calcium, phosphorus,', 'magnesium, creatinine, BUN, glucose, ALT, bilirubin, urinalysis, total protein,', 'albumin, CPK, and chromogranin A. Evaluation of catecholamine production by', 'tumor (serum normetanephrine and metanephrine, urine if possible) will be performed', 'in patients with PHEO/PGL only.', '4.2.5', 'Urine or serum pregnancy test for all females of childbearing potential.', '4.2.6', 'Pathologic/Tissue Evaluation', 'Pathologic diagnosis will be reviewed and verified at the Clinical Center. Expression', 'of SDH complex subunits and/or FH will be evaluated by immunohistochemistry in', 'available pre-treatment tumor samples in the Clinical Center Laboratory of Pathology.', 'GIST without Kit or PDGFRA mutation will be determined using standard approved', 'tests.', '4.2.7', 'For patients with PHEO/PGL', 'Germline SDH subunit mutations will be determined using standard approved testing.', 'Approved testing done outside of the Clinical Center will be accepted for these', 'patients.', '4.3', 'REGISTRATION PROCEDURES', '4.3.1', 'IWRS', 'Patient Enrollment will be facilitated using the Interactive Web Response System (IWRS).', 'IWRS is a web-based registration system available to users on a 24/7 basis. On a successful', 'registration, IWRS will assign a patient number and assign the treatment. Patient enrollment', ""data entered by Registrars in IWRS will automatically transfer to the NCI's clinical data"", 'management system, Medidata Rave. IWRS will provide a printable confirmation of', 'registration and treatment information. Please retain a copy of this confirmation for your', 'records.', 'Users must have a valid CTEP-IAM account (i.e., CTEP username and password) to', 'access the IWRS system.', 'Users defined with the Registrar role will have the ability to register patient in the', 'study.', 'Users defined with the Client Administrator role will have the ability to manage', 'accrual limits, open and close treatment assignments as well as approve slot', 'reservations, if applicable to the study.', '4.3.2 OPEN/IWRS', 'Patient enrollment will be facilitated using the Oncology Patient Enrollment Network', '(OPEN). OPEN is a web-based registration system available to users on a 24/7 basis. It is', 'integrated with the CTSU Enterprise System for regulatory and roster data interchange and', 'with the Theradex Interactive Web Response System (IWRS) for retrieval of patient', 'registration/randomization assignment. Patient enrollment data entered by Registrars in']"
20,page_21,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '21', 'Version Date: 07/22/2019', ""OPEN/IWRS will automatically transfer to the NCI's clinical data management system,"", 'Medidata Rave.', 'The OPEN system will provide the site with a printable confirmation of registration and', 'treatment information. Please retain a copy of this confirmation for your records.', '4.3.3 OPEN/IWRS User Requirements', 'OPEN/IWRS users must meet the following requirements:', 'Have a valid CTEP-IAM account (i.e., CTEP username and password).', 'To enroll patients: Be on an ETCTN Corresponding or Participating Organization', 'roster with the role of Registrar.', 'Have regulatory approval for the conduct of the study at their site.', 'Prior to accessing OPEN/IWRS, site staff should verify the following:', 'All eligibility criteria have been met within the protocol stated timeframes.', 'If applicable, all patients have signed an appropriate consent form and HIP AA', 'authorization form.', '4.3.4 OPEN/IWRS Questions?', 'Further instructional information on OPEN is provided on the OPEN tab of the CTSU', 'website at https://www.ctsu.org or at https://open.ctsu.org. For any additional questions', 'contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact(awestat.com.', '4.4 LOCAL Registration FORNCICCR', 'Authorized staff must register an eligible candidate with NCI Central Registration Office', '(CRO) within 24 hours of signing consent. A registration Eligibility Checklist from the', 'website (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm) must be completed and', 'sent via encrypted email to: NCI Central Registration Office ncicentralregistration-', 'l@mail.nih.gov. After confirmation of eligibility at Central Registration Office, CRO staff', 'will call pharmacy to advise them of the acceptance of the patient on the protocol prior to the', 'release of any investigational agent. Verification of Registration will be forwarded', 'electronically via e-mail to the research team. A recorder is available during non-working', 'hours.', '5', 'STUDY IMPLEMENTATION', '5.1 STUDY DESIGN', 'This is a single site, open label, phase II study design using a small optimal two-stage design', 'to evaluate the clinical response in three groups of patients:', '1. wild-type GIST (GIST without Kit or PDGFRA mutation)', '2. PHEO/PGL in patients with germline SDH subunit mutation (SDH deficient', 'PHEO/PGL), or', '3. RCC associated with HLRCC', 'Adults and children (greater than or equal to 12 years of age) with measurable localized or', 'metastatic or unresectable wild-type GIST, SDH deficient PHEO/PGL, or HLRCC-associated']"
21,page_22,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '22', 'Version Date: 07/22/2019', 'RCC will be eligible for trial participation. SGI-110 will be administered subcutaneously at', '45mg/m²/day X 5days on a 28-day cycle. Cycles may be repeated until there is evidence of', 'tumor progression clinically or by RECISTv1.1 or there is intolerable toxicity that is not', 'alleviated by dose reduction.', 'SGI-110 activity will be assessed by radiographic response of measurable disease using', 'RECISTv1.1. Patients will be carefully monitored for toxicity and response. Time to', 'progression, overall survival and quality of life will be evaluated as secondary objectives.', '5.2 DRUG ADMINISTRATION', 'SGI-110 will be administered subcutaneously, preferably in the abdominal area at', '45mg/m²/day x 5 days on a 28-day cycle. SGI-110 is available in a two-vial system, (1) SGI-', '110 for Injection 100 mg, and (2) SGI-110 Diluent for Reconstitution 3 mL.', 'SGI-110 drug product admixed with the custom diluent as described in section 15.1. The', 'reconstituted SGI-110 solution is stable for 1 week under refrigerated conditions.', 'SGI-110 should be injected slowly (up to one minute) as some injection site discomfort or', 'pain may be experienced. Care must be taken to avoid intradermal injection as this may result', 'in injection site pain. To prevent injection site pain, patient should be directed to apply ice', 'packs to the injection site before and after the injection. If the injection pain continues', 'despite these measures, pre-treatment with topical or systemic analgesics may be considered.', 'Patients will be observed in clinic for at least one hour after the first dose of SGI-110.Vital', 'signs including blood pressure, heart rate, and respiratory rate will be obtained and injection', 'site will be monitored for signs of local reaction every 20-30 minutes in clinic for 1-hour post', 'injection after the initial dose of SGI-110.', '5.3 DOSEMODIFICATIONS', 'Although not a phase 1 study, toxicity will be evaluated and treatment limited by the', 'toxicities defined below. This study will utilize the CTEP Common Terminology Criteria for', 'Adverse Events (CTCAE) Version 5.0 for toxicity and Adverse Event grading and reporting.', 'An adverse event must be judged to be possibly, probably, or definitely related to SGI-110 to', 'be a treatment limiting toxicity. Because it is possible that longer-term administration of the', 'drug may be required in these patient populations, two dose reductions of approximately 30%', 'will be allowed for patients who develop toxicity determined to be treatment related.', 'If a subject misses or skips a dose the dose will be given the next day. When a missed or', 'skipped dose occurs, the research team should be notified to provide guidelines to the subject', 'on whether to proceed with further doses.', 'SGI-110 will be held for treatment-limiting toxicities and re-started at the reduced dose after', 'resolution of toxicity to a grade 1 or baseline.', 'Treatment-limiting toxicity is defined as:', 'Toxicities that are possibly, probably or definitely related to SGI-110 and are > grade', '3, unless the toxicity resolves/reversible within 72 hours with supportive care.', 'In addition, persistent grade 2 toxicities will be considered dose-limiting if they are', 'intolerable to the patient.', 'If the patient experiences a treatment limiting toxicity after two dose reductions, SGI-110 will', 'be discontinued permanently.']"
22,page_23,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '23', 'Version Date: 07/22/2019', 'Dose Level', 'Dose reduction (mg/m²/dose)', 'Dose reduction (%)', 'Dose 1', '30mg/m²/dose', '~30%', 'Dose -2', '20mg/m²/dose', '~30%', '5.4 QUESTIONNAIRES (APPENDIX III AND APPENDIX IV)', 'The pediatric PROMIS instruments and the Distress Rating Tool will be administered to all', 'consenting patients who speak English or Spanish with parallel Parent Proxy instruments', 'administered to parents of patients ages 12-17. These instruments will be administered at', 'baseline, at the end of cycle 4 and every 4 cycles thereafter, and at the time a patient is taken', 'off treatment (see Section 5.7). Since the measures have not been validated in other', 'languages, participation in this portion of the study will be limited to subjects who speak', 'either English or Spanish.', '5.4.1 PROMIS', 'The Patient-Reported Outcome Measurement Information System (PROMIS), funded by', 'the National Institutes of Health to provides clinicians and researchers access to efficient,', 'precise, valid, and responsive parent- and child-reported measures of health and well-being.', '5.4.2 Distress Rating Tool', 'All patients ages 12 years or older will complete the Distress Thermometer. The Distress', 'Thermometer takes less than 5 minutes to complete.', '5.5 ON-STUDY EVALUATION', '5.5.1 Baseline Assessment', 'Laboratory values must be no older than 72 hours from the time of eligibility evaluation and', 'starting therapy. Imaging studies must be no older than 4 weeks of enrollment at enrollment.', 'Testing outside of this window must be repeated prior to starting study drug.', 'If a post-enrollment/pre-treatment laboratory value is outside of the limits of eligibility, this', 'laboratory value must return to the eligibility requirement prior to initiating therapy. If the', 'laboratory value does not return to the limits of eligibility within 14 days, patient may not', 'receive protocol therapy.', 'The evaluations required prior to starting treatment portion of the study are listed in Section', '5.6, Study Calendar. Screening labs will be repeated if they are older than 72 hours.']"
23,page_24,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '24', 'Version Date: 07/22/2019', '5.6 STUDY CALENDAR', 'Post Therapy', 'Follow-up', '(approximately', '30 days after', 'Subsequent Cycles (', 'final dose of', 'Cycle 1 (I 3 days)', '3 days)', 'study drug)', 'Day 2-', 'Day', 'Procedure', 'Screening', 'Baseline', 'Day 1', '5', 'Day 7', '14', 'Day 28', 'Day 1-5', 'Day 28', 'History', 'X', 'X', 'Physical Exam', 'X', 'Xa', 'X', 'Vital signs', 'X', 'X', 'Xi', 'X', 'Performance Score', 'X', 'Xa', 'SGI-110 Administration', 'X', 'X', 'X', 'Labs', 'Complete blood countwith', 'diff, platelets', 'Electrolytes (including', 'sodium, potassium,', 'chloride, CO2), calcium,', 'X', 'Xa', 'X', 'phosphorus, magnesium,', 'creatinine, BUN, glucose,', 'ALT, bilirubin, urinalysis,', 'total protein, albumin, and', 'CPK', 'Serum normetanephrine', 'and metanephrine (if', 'possible, urine), and', 'X', 'Xi', 'chromogranin A (in', 'patients with PHEO/PGL', 'only)']"
24,page_25,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '25', 'Version Date: 07/22/2019', 'Post Therapy', 'Follow-up', '(approximately', '30 days after', 'Subsequent Cycles (', 'final dose of', 'Cycle 1 (I 3 days)', '3 days)', 'study drug)', 'Day 2-', 'Day', 'Procedure', 'Screening', 'Baseline', 'Day 1', '5', 'Day 7', '14', 'Day 28', 'Day 1-5', 'Day 28', 'Urine/serum pregnancy test', 'for all females of', 'X', 'Xk', 'childbearing potential', 'Biopsies', 'Xc', 'Xg', '1) Tumorexpression ofSDH', 'complex subunits and FH', 'X', 'Xg', 'by IHC', '2) Tumorexpression of NY-', 'Xf', 'Xg', 'ESO-1 by IHC', 'LINE-1 demethylation', 'analysis (Dr. Meltzer', 'X', 'X', 'research)', 'Pharmacokinetic testing', 'X', 'Xd', 'Xd', 'Pharmacodynamic testinge', 'X', 'X', 'X', 'X', 'Response evaluation of', 'X', 'Xb', 'Xb', 'disease b', 'Quality of Life (Distress', 'X', 'Xh', 'Xh', 'thermometerand PROMIS)', 'Adverse Events', 'X', 'X', 'Concomitant Medications', 'X', 'X', 'a', 'Laboratory tests older than 2 weeks (14 days) at the start of therapy must be repeated. For abnormal test results,', 'refer', 'to', 'Section', '4.2.', 'b Imaging studies will be repeated if older than 4 weeks at the start of therapy. Imaging evaluation selection may include CT and/or MRI, and/or FDG-PET', 'as clinically indicated. Staging should be performed prior to the second cycle and then prior to every other cycle. The same imaging strategy will be used', 'throughout study participation for tumor evaluation.']"
25,page_26,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '26', 'Version Date: 07/22/2019', 'c when archival tissue is not available.', 'd active metabolite (decitabine) will be assayed in plasma prior to first dose in cycle 1 and at 0.5 hour (+/- 15 minutes), 1 hour (+/- 15 minutes), 2 hour', '(+/-', '30 minutes), 4 hour (+/- 30 minutes), 6 hour (+/- 1 hour) and 24 hours (+/-2 hours) after the first dose of drug in Cycle 1.', 'e', 'LINE-1 demethylation in PBMC using pyrosequencing and urine and plasma glycolytic metabolytes at baseline and day 7, 14, and 28 of cycle 1.', 'f pre-treatment tumor samples on archival tissue may be used for initial NY-ESO-1 evaluation.', 'g On-treatment biopsy will be performed when a core biopsy may be safely performed in consenting patients > 18 years of age. On treatment biopsy will be', 'optional.', 'hat the end of cycle 4 and then every 4 cycles thereafter (e.g. at the end of cycle 8, 12, 16, etc.), and at the end of therapy.', 'iVital signs will be obtained on day 1 per section 5.2.', 'jAt each restaging timepoint', 'kPrior to each cycle']"
26,page_27,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '27', 'Version Date: 07/22/2019', '5.7 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA', 'Prior to removal from study, effort must be made to have all subjects complete a safety visit', 'approximately 30 days following the last dose of study therapy.', '5.7.1 Criteria for removal from protocol therapy', 'Patients participating in this study may be removed for therapy with SGI-110 due to any one of', 'the following events:', 'Completed 30-day safety follow-up period', 'Progressive disease', 'Participant requests to be withdrawn from active therapy', 'Unacceptable Toxicity as defined in Section 5.3', 'Investigator discretion', 'Positive pregnancy test', '5.7.2 Off-Study Criteria', 'Patients who are removed from treatment permanently for any reason should be monitored until', 'resolution or stabilization of toxicity, or until 30 days after the last dose of SGI-110, whichever', 'is', 'later. In addition, the following criteria will result in removal from study:', 'Participant requests to be withdrawn from study', 'Lost to follow up', 'Death', '5.7.3 Off Protocol Therapy and Off-Study Procedure', 'Authorized staff must notify Central Registration Office (CRO) when a subject is taken off', 'protocol therapy and when a subject is taken off-study. A Participant Status Updates Form from', 'the website (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm) main page must be', 'completed and sent via encrypted email to: NCI Central Registration Office', 'ncicentralregistration-l@mail.nih.gov.', 'Note: all minors will be kept on study and followed until the age of 18 to allow for consent.', '6 CONCOMITANT MEDICATIONS/MEASURES', 'There will be no concomitant disease directed therapy allowed while patients are participating in', 'this study.', 'Supportive standard therapies and preventive measures should be instituted to address known', 'toxicities, including the following:', '6.1 INJECTION SITE REACTIONS', 'Care must be taken to avoid intradermal injection, and administer by slow subcutaneous', 'injection. If injection site pain occurs, apply ice packs to the site both before and after injection.']"
27,page_28,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '28', 'Version Date: 07/22/2019', 'If injection site reactions occur despite these measures, pre-treatment with topical or systemic', 'analgesic can be considered.', '6.2 MUCOSITIS', 'To prevent mucositis, participants should be directed to increase brushing teeth with the softest', 'tooth brush, every 4 hours and at bedtime, and rinse frequently with mouth rinses, to keep the', 'mouth moisturized. Patients with a healthy mouth may use non-alcoholic mouthwash 4 to 6', 'times daily (e.g. after each meal), or according to the instructions, during the study.', 'Saline mouthwashes (Sodium chloride 0.9%) are preferred in cases of stomatitis, and should be', 'used at a different time than toothbrushing (e.g. aftertea).', 'Consider treating stomatitis at an early stage (CTCAE grade 1) or as soon as the patient', 'complains of a sore mouth. Consider using an oral topical analgesic, with or without topical', ""steroids, depending on the patient's clinical condition and the local standard medical practice."", '6.3 DIARRHEA', 'Patients should be made aware that they may experience diarrhea, and should record the number', 'of stools and associated symptoms. Patients should inform the physician if they develop', 'diarrhea. The following dietary advice should be considered: BRAT diet (bananas, rice, apple', 'sauce, toast, plain pasta), readily digestible food, avoidance of lactose-containing products and', 'fried, fatty or spicy foods, increased fluid intake (8-10 glasses of clear fluids/day (including', 'water, clear broth, fluids containing salt and sugar). Patients should be given loperamide to take', 'home and should start taking loperamide after the first episode of unformed, loose stool. If', 'diarrhea persists and after consulting with the investigator, loperamide can be continued at a dose', 'of 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours. During the night, the', 'patient may take 4 mg of loperamide every 4 hours. Monitor and replace fluid and electrolytes.', 'Patients should contact their physician or study nurse if they have persistent diarrhea, diarrhea', 'complicated by vomiting or fever, or inability to take oral liquids', '7', 'BIOSPECIMEN COLLECTION', '7.1', 'CORRELATIVE STUDIES FOR RESEARCH/PHARMACOKINETIC STUDIES', '7.1.1 Pharmacokinetics', 'Pharmacokinetic analysis will be performed in patients during cycle 1 according to Section 5.6,', 'Study Calendar. The observed decitabine T1/2 following SC administration of SGI-110 in adults', 'is 2.4 hours23. The active metabolite of SGI-110 (decitabine) will be assayed in plasma prior to', 'the first dose of drug in cycle 1 and at 0.5 (+/- 15 min), 1 (+/- 15 min), 2 (+/- 30 min), 4 (+/- 30', 'min), 6 (+/- 1 hour), and 24 hours (+/- 2 hours). Blood samples (3mL) will be collected into 6', 'mL sodium heparin green top tubes. PK analysis will be performed in the laboratories of Dr.', 'Figg. Plasma levels of decitabine will be determined using a validated liquid chromatography-', 'mass spectrometry method.', 'This PK data will be used to develop a population PK model (using Phoenix NLME®, Certara,', 'Cary, NC and RStudio) that will assess the impact of covariates including (but not limited to)', 'age, body size (weight, height, surface area), sex, race, PD endpoints, hepatic and renal function.']"
28,page_29,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '29', 'Version Date: 07/22/2019', 'The degree of change in decitabine PK based on the covariates available will be assessed to', 'determine if dose adjustments are required.', '7.1.2 Expression of SDH complex subunits and FH', 'Expression of SDH complex subunits and FH will be evaluated by immunohistochemistry in', 'available pre-treatment and on treatment tumor samples in the Clinical Center Laboratory of', 'pathology under the direction of Dr. Marino and Dr. Miettenen. This analysis will be performed', 'in archival tumor tissue and in on-treatment biopsies when available. Paraffin-embedded tissue', 'sections will be utilized for this analysis and staining will be performed using published', 'methodology that was developed in the laboratory of pathology for FH, SDHA and SDHB2,33', '7.1.3 DNA hyper-methylation', 'The DNA-methylome will be evaluated for pre-treatment and on-treatment tumor biopsies (when', 'available) in the laboratory of Dr. Paul Meltzer. Methylation assay and methylation data analysis', 'will be done using paraffin-embedded samples. The EZ DNA Methylation kit (Zymo Research)', 'will be used for bisulfite conversion of gDNA extracted from paraffin-embedded tumor samples.', 'The GoldenGate Cancer Panel Methylation Array 1 (Illumina) will be utilized and data analyzed', 'as previously described2.', '7.1.4 NY-ESO-1 expression', 'Available pre-treatment tumor samples will be used for initial NY-ESO- evaluation and on-', 'treatment biopsies will be optional for patients >18 years old when core biopsy can be safely', 'performed. NY-ESO-1 expression before and on treatment in paired tumor biopsy samples when', 'available, using immunohistochemistry in the Laboratory of Pathology at the Clinical Center', 'under the direction of Dr. Miettenen and Dr. Marino. Paraffin-embedded tissue sections will be', 'utilized for this analysis and staining will be performed using published methodology that was', 'developed in the laboratory of pathology34. NY-ESO-1 staining intensity will be assessed by two', 'pathologists using the following scoring system: 1+ = weak, 2+ = moderate, 3+ = strong.', '7.1.5 Serum and Urine Concentrations of glycolytic metabolites', 'Impaired activity of the Krebs cycle enzymes SDH complex or FH leads to aberrant cellular', 'concentrations of glycolytic metabolites including fumarate and succinate 35,36 Systemic levels of', '2-hydroxyglutarate have been investigated as a method of identifying patients with glioblastoma', 'with isocitrate dehydrogenase mutation37. In these patients, the plasma/urine ratio of 2-', 'hydroxyglutarate was significantly different between patients with mutant isocitrate', 'dehydrogenase enzymes. Systemic levels of glycolytic metabolites are not well-defined in', 'patients with wt-GIST, HLRCC, or PHEO/PGL. We will begin to explore the metabolomic', 'profile of patients with tumors related to Krebs cycle defects. Serum and urine 2-', 'hydroxyglutarate, succinate, and fumarate will be determined at baseline and on treatment.', 'Plasma and urine samples will be collected at baseline and on day 7, 14, and 28 of cycle 1.', 'Urine samples will be cooled to 4 C, centrifuged, aliquoted and stored at -80 C until analysis.', 'Blood samples (3mL) will be collected in EDTA tubes and cooled to IC, centrifuged, and', 'plasma will be aliquoted and stored at -80 C until analysis. Concentrations of 2-hydroxyglutarate', 'succinate and fumarate will be analyzed using liquid chromatography/mass spectrometry', '(LC/MS) as previously described37,38']"
29,page_30,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '30', 'Version Date: 07/22/2019', '5.1.6 LINE-1 demethylation analysis of PBMCs', 'LINE-1 methylation status in peripheral blood mononuclear cells will be assessed as an estimate', 'of global DNA methylation. This analysis will be performed on samples at baseline and on days', '7, 14, and 28 of cycle 1. Analysis will be performed in the laboratory of Dr. Meltzer using a', 'previously described quantitative bisulfate pyrosequencing method39', 'Study', 'Test/Lab Location', 'Sample Time', 'Volume/type of blood', 'Tube', 'Notes', 'Points', 'sample', 'PK- analysis of', 'Liquid', 'Pre-dose 1, and', '3mL blood', '6 mL', 'Tubes will be', 'decitabine', 'Chromatography-mass', '0.5, 1, 2, 4, 6,', 'sodium', 'cooled to 4', 'spectrometry method,', 'and 24 hrs post', 'heparin', 'degrees C and', ""Dr. Figg's lab"", 'dose 1', 'green top', 'centrifuged.', 'Plasma will be', 'aliquoted and', 'storedat -80 C', 'until analysis.', 'Expression of', 'IHC, CC Laboratory', 'If available:', 'Archival samples may be', 'NA', 'SDH complex', 'of Pathology (Dr.', 'prior to dose 1', 'used for pretreatment, on', 'subunits and FH y', 'Marino and Dr.', 'and during', 'treatment biopsies', 'Block (can be', 'Miettenen', 'treatment', 'performed in patients > 18', 'same block that', 'years, if safely obtainable.', 'is used for', 'NY-ESO-1', 'IHC, CC Laboratory', 'If available,', 'Archival samples may be', 'NA', 'DNA', 'expression', 'of Pathology (Dr.', 'prior to dose 1', 'used for pretreatment, on', 'hypermethylati', 'Marino and Dr.', 'and during', 'treatment biopsies', 'on) or 10', 'Miettenen', 'treatment', 'performed in patients > 18', 'unstained slides', 'years, if safely obtainable.', 'Samples will be', 'fixed and', 'processed by', 'the laboratory', 'of pathology.', 'DNA', 'EZ DNA Methylation', 'Prior to dose 1', 'Archival samples may be', 'NA', 'Block (can be', 'hypermethylation', 'kit (Zymo Research)', 'and during', 'used for pretreatment, on', 'same block that', 'will be used for', 'treatment', 'treatment biopsies', 'is used for NY-', 'bisulfite conversion of', 'performed in patients> 18', 'ESO-1', 'gDNA, and The', 'years, if safely obtainable.', 'expression)', 'GoldenGate Cancer', 'or 10 unstained', 'Panel Methylation', 'slides of FFPE', 'Array 1 (Illumina)', 'samples will be', 'will be utilized in the', 'supplied to Dr.', 'laboratory of Dr. Paul', ""Meltzer's"", 'Meltzer', 'laboratory for', 'processing.', 'LINE-1', 'EZ DNA Methylation', 'Prior to dose 1', '10 mL blood', 'lavender', 'Samples will be', 'demethylation', 'kit (Zymo Research)', 'and Cycle 1,', 'top', 'collectedand', 'analysis', 'will be used for', 'Day 14 (=3', 'spun by Dr.', 'bisulfite conversion of', 'days)', ""Figg's Lab and"", 'gDNA, and The', 'then sent to', 'GoldenGate Cancer', ""Paul Meltzer's"", 'Panel Methylation', 'lab. PBMC will', 'Array 1 (Illumina)', 'be collected and', 'will be utilized in the', 'aliquoted and', 'laboratory of Dr. Paul', 'storeduntil', 'Meltzer', 'analysis.']"
30,page_31,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '31', 'Version Date: 07/22/2019', 'Study', 'Test/Lab Location', 'Sample Time', 'Volume/type of blood', 'Tube', 'Notes', 'Points', 'sample', 'Urine glycolytic', 'LC/MS', 'At baseline at', 'Urine samples 10-15 ml', '15ml', 'Samples will be', 'metabolites (PD)', 'Laboratory of Dr.', 'days 7, 14, and', 'Conical', 'collected. and', 'Widemann', '28 of cycle 1.', 'tube', 'cooled to 4 C.', ""Dr. Figg's lab"", 'to process:', 'spin briefly to', 'remove debris.', 'Sample will', 'then be', 'aliquoted and', 'stored at -80 C', 'until analysis.', 'Serum glycolytic', 'LC/MS', 'At baseline at', 'Blood sample 3mL', '3 ml SST', 'Samples will be', 'metabolites (PD)', 'Laboratory of Dr.', 'days 7, 14, and', 'collected and', 'Widemann', '28 of cycle 1.', 'cooled to 4 C.', ""Dr. Figg's lab"", 'to process:', 'Spin, and', 'Plasma will', 'then be', 'aliquoted and', 'storedat -80 C', 'until analysis.', '7.2 SAMPLE STORAGE, TRACKING AND DISPOSITION', 'All samples sent to the Clinical Pharmacology Program (CPP) will be barcoded with data', 'entered and stored in the Patient Sample Data Management System (a.k.a LabSamples) utilized', 'by the CPP. This is a secure program, with access to LabSamples limited to defined CPP', 'personnel, who are issued individual user accounts. Installation of LabSamples is limited to', 'computers specified by Dr. Figg. These computers all have a password restricted login screen.', 'All CPP personnel with access to patient information annually complete the NIH online', 'Protection of Human Subjects course.', 'LabSamples creates a unique barcode ID for every sample and sample box, which cannot be', 'traced back to patients without LabSamples access. The data recorded for each sample includes', 'the patient ID, name, trial name/protocol number, time drawn, cycle time point, dose, material', 'type, as well as box and freezer location, and date samples are sent to the investigator or shipped', 'to outside institutions. Patient demographics associated with the clinical center patient number', 'are provided in the system. For each sample, there are notes associated with the processing', 'method (delay in sample processing, storage conditions on the ward, etc.).', '7.2.1 Sample Storage and Destruction', 'Barcoded samples are stored in barcoded boxes in a locked freezer at - -80°C in accordance to', 'stability requirements. These freezers are located onsite in the CPP and offsite at NCI Frederick', 'Central Repository Services in Frederick, MD. Visitors to the laboratory are required to be', 'accompanied by laboratory staff at all times.', 'Access to stored clinical samples is restricted. Samples will be stored until requested by a', 'researcher named on the protocol. All requests are monitored and tracked in LabSamples. All']"
31,page_32,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '32', 'Version Date: 07/22/2019', 'researchers are required to sign a form stating that the samples are only to be used for research', 'purposes associated with this trial (as per the IRB approved protocol) and that any unused', 'samples must be returned to the CPP. It is the responsibility of the NCI Principal Investigator to', 'ensure that the samples requested are being used in a manner consistent with IRB approval.', 'Following completion of this study, samples will remain in storage as detailed above. Access to', 'these samples will only be granted following IRB approval of an additional protocol, granting', 'the rights to use the material.', 'If, at any time, a patient withdraws from the study and does not wish for their existing samples to', 'be utilized, the individual must provide a written request. Following receipt of this request, the', 'samples will be destroyed (or returned to the patient, if so requested), and reported as such to the', 'IRB. The PI will record any loss or unanticipated destruction of samples as a deviation.', 'Reporting will be per the requirements of section 10.2.1.', 'Sample barcodes are linked to patient demographics and limited clinical information. This', 'information will only be provided to investigators listed on this protocol, via registered use of the', 'LabSamples. It is critical that the sample remains linked to patient information such as race, age,', 'dates of diagnosis and death, and histological information about the tumor, in order to correlate', 'genotype with these variables.', 'The study will remain open and status reported to the NIH Intramural IRB until all samples have', 'been analyzed, reported or destroyed. Unintentional loss or destruction of any samples will be', 'reported to the NIH Intramural IRB per the requirements of section 10.2.1. Any use of these', 'samples for purposes not described in this protocol will require prospective NIH Intramural IRB', 'review and approval.', 'Data from patient reported outcomes and functional endpoints will be sent to POB NCI for data', 'analysis. All data will be identified using the study number; no personal identifying information', 'should be sent to NCI.', '8', 'MEASUREMENT OF EFFECT', 'For the purposes of this study, patients should be re-evaluated for response after the first 4 weeks', 'and then every 8 weeks. In addition to a baseline scan, confirmatory scans should also be', 'obtained 4 weeks following initial documentation of objective response.', 'Response and progression will be evaluated in this study using the new international criteria', 'proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline', '(version 1.1) [Eur J Ca 45:228-247, 2009]. Changes in the largest diameter (unidimensional', 'measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph', 'nodes are used in the RECIST criteria.', '8.1 DEFINITIONS', 'Evaluable for toxicity: All patients will be evaluable for toxicity from the time of their first', 'treatment with SGI-110.', 'Evaluable for objective response: Only those patients who have measurable disease present at', 'baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will', 'be considered evaluable for response. These patients will have their response classified']"
32,page_33,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '33', 'Version Date: 07/22/2019', 'according to the definitions stated below. (Note: Patients who exhibit objective disease', 'progression prior to the end of cycle 1 will also be considered evaluable.)', 'Evaluable Non-Target Disease Response: Patients who have lesions present at baseline that are', 'evaluable but do not meet the definitions of measurable disease, have received at least one cycle', 'of therapy, and have had their disease re-evaluated will be considered evaluable for non-target', 'disease. The response assessment is based on the presence, absence, or unequivocal progression', 'of the lesions.', '8.2 DISEASE PARAMETERS', 'Measurable disease: Measurable lesions are defined as those that can be accurately measured in', 'at least one dimension (longest diameter to be recorded) as >20 mm by chest x-ray, as >10 mm', 'with CT scan, or >10 mm with calipers by clinical exam. All tumor measurements must be', 'recorded in millimeters (or decimal fractions of centimeters).', 'Note: Tumor lesions that are situated in a previously irradiated area might or might not be', 'considered measurable. If the investigator thinks it appropriate to include them, the conditions', 'under which such lesions should be considered must be defined in the protocol.', 'Malignant lymph nodes. To be considered pathologically enlarged and measurable, a lymph', 'node must be >15 mm in short axis when assessed by CT scan (CT scan slice thickness', 'recommended to be no greater than 5 mm). Atbaseline and in follow-up, only the short axis will', 'be measured and followed.', 'Non-measurable disease. All other lesions (or sites of disease), including small lesions (longest', 'diameter <10 mm or pathological lymph nodes with >10 to <15 mm short axis), are considered', 'non-measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial', 'effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses', '(not followed by CT or MRI), are considered as non-measurable.', 'Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should not', 'be considered as malignant lesions (neither measurable nor non-measurable) since they are, by', 'definition, simple cysts.', ""'Cystic lesions' thought to represent cystic metastases can be considered as measurable lesions,"", 'if they meet the definition of measurability described above. However, if non-cystic lesions are', 'present in the same patient, these are preferred for selection as target lesions.', 'Target lesions. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in', 'total, representative of all involved organs, should be identified as target lesions and recorded', 'and measured at baseline. Target lesions should be selected on the basis of their size (lesions', 'with the longest diameter), be representative of all involved organs, but in addition should be', 'those that lend themselves to reproducible repeated measurements. It may be the case that, on', 'occasion, the largest lesion does not lend itself to reproducible measurement in which', 'circumstance the next largest lesion which can be measured reproducibly should be selected. A', 'sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target', 'lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be', 'included in the sum, then only the short axis is added into the sum. The baseline sum diameters']"
33,page_34,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '34', 'Version Date: 07/22/2019', 'will be used as reference to further characterize any objective tumor regression in the measurable', 'dimension of the disease.', 'Non-target lesions. All other lesions (or sites of disease) including any measurable lesions over', 'and above the 5 target lesions should be identified as non-target lesions and should also be', 'recorded at baseline. Measurements of these lesions are not required, but the presence, absence,', 'or in rare cases unequivocal progression of each should be noted throughout follow-up.', '8.2.1 Methods for Evaluation of Measurable Disease', 'All measurements should be taken and recorded in metric notation using a ruler or calipers. All', 'baseline evaluations should be performed as closely as possible to the beginning of treatment and', 'never more than 4 weeks before the beginning of the treatment.', 'The same method of assessment and the same technique should be used to characterize each', 'identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is', 'preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be', 'imaged but are assessable by clinical exam.', 'Clinical lesions: Clinical lesions will only be considered measurable when they are superficial', '(e.g., skin nodules and palpable lymph nodes) and >10 mm diameter as assessed using calipers', '(e.g., skin nodules). In the case of skin lesions, documentation by color photography, including a', 'ruler to estimate the size of the lesion, is recommended.', 'Chest x-ray: Lesions on chest x-ray are acceptable as measurable lesions when they are clearly', 'defined and surrounded by aerated lung. However, CT is preferable.', 'Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan', 'based on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice thickness', 'greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.', 'MRI is also acceptable in certain situations (e.g. for body scans).', 'Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal', 'resolution; however, there are many image acquisition variables involved in MRI, which greatly', 'impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of', 'MRI is variable globally. As with CT, if an MRI is performed, the technical specifications of the', 'scanning sequences used should be optimized for the evaluation of the type and site of disease.', 'Furthermore, as with CT, the modality used at follow-up should be the same as was used at', 'baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond', 'the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all', 'scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the', 'image acquisition protocol should be followed as closely as possible to prior scans. Body scans', 'should be performed with breath-hold scanning techniques, if possible.', 'PET-CT: At present, the low dose or attenuation correction CT portion of a combined PET-CT', 'is not always of optimal diagnostic CT quality for use with RECIST measurements. However, if', 'the site can document that the CT performed as part of a PET-CT is of identical diagnostic', 'quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be', 'used for RECIST measurements and can be used interchangeably with conventional', 'CT', 'in', 'accurately measuring cancer lesions over time. Note, however, that the PET portion of the CT']"
34,page_35,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '35', 'Version Date: 07/22/2019', 'introduces additional data which may bias an investigator if it is not routinely or serially', 'performed.', 'Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a', 'method of measurement. Ultrasound examinations cannot be reproduced in their entirety for', 'independent review at a later date and, because they are operator dependent, it cannot be', 'guaranteed that the same technique and measurements will be taken from one assessment to the', 'next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT', 'or MRI is advised. If there is concern about radiation exposure at CT, MRI may be used instead', 'of CT in selected instances.', 'Endoscopy, Laparoscopy: The utilization of these techniques for objective tumor evaluation is', 'not advised. However, such techniques may be useful to confirm complete pathological', 'response when biopsies are obtained or to determine relapse in trials where recurrence following', 'complete response (CR) or surgical resection is an endpoint.', 'Tumor markers: Tumor markers alone cannot be used to assess response. If markers are initially', 'above the upper normal limit, they must normalize for a patient to be considered in complete', 'clinical response. Specific guidelines for both CA-125 response (in recurrent ovarian cancer)', 'and PSA response (in recurrent prostate cancer) have been published [JNCI96:487-488, 2004; J', 'Clin Oncol 17, 3461-3467, 1999; J Clin Oncol 26:1148-1159, 2008]. In addition, the', 'Gynecologic Cancer Intergroup has developed CA-125 progression criteria which are to be', 'integrated with objective tumor assessment for use in first-line trials in ovarian cancer [JNCI', '92:1534-1535, 2000].', 'Cytology, Histology: These techniques can be used to differentiate between partial responses', '(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as', 'germ cell tumors, where known residual benign tumors can remain).', 'The cytological confirmation of the neoplastic origin of any effusion that appears or worsens', 'during treatment when the measurable tumor has met criteria for response or stable disease is', 'mandatory to differentiate between response or stable disease (an effusion may be a side effect of', 'the treatment) and progressive disease.', 'FDG-PET: While FDG-PET response assessments need additional study, it is sometimes', 'reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in', ""assessment of progression (particularly possible 'new' disease). New lesions on the basis of"", 'FDG-PET imaging can be identified according to the following algorithm:', 'a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD', 'based on a new lesion.', 'b. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-', 'PET at follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the', 'positive FDG-PET at follow-up is not confirmed as a new site of disease on CT,', 'additional follow-up CT scans are needed to determine if there is truly progression', 'occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG-', 'PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing site of', 'disease on CT that is not progressing on the basis of the anatomic images, this is not PD.']"
35,page_36,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '36', 'Version Date: 07/22/2019', 'c.', 'FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in', 'cases where a residual radiographic abnormality is thought to represent fibrosis or', 'scarring. The use of FDG-PET in this circumstance should be prospectively described in', 'the protocol and supported by disease-specific medical literature for the indication.', 'However, it must be acknowledged that both approaches may lead to false positive CR', 'due to limitations of FDG-PET and biopsy resolution/sensitivity.', 'Note: A ""positive\' FDG-PET scan lesion means one which is FDG avid with an uptake greater', 'than twice that of the surrounding tissue on the attenuation corrected image.', '8.2.2 Response Criteria', '8.2.2.1 Evaluation of Target Lesions', 'Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes', '(whether target or non-target) must have reduction in short axis to <10 mm.', 'Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions,', 'taking as reference the baseline sum of diameters.', 'Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions,', 'taking as reference the smallest sum on study (this includes the baseline sum if that is the', 'smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an', 'absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also', 'considered progressions).', 'Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to', 'qualify for PD, taking as reference the smallest sum of diameters while on study.', 'Evaluation of Non-Target Lesions', 'Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor', 'marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).', 'Note: If tumor markers are initially above the upper normal limit, they must normalize for a', 'patient to be considered in complete clinical response.', 'Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor', 'marker level above the normal limits.', 'Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal', 'progression of existing non-target lesions. Unequirocal progression should not normally trump', 'target lesion status. It must be representative of overall disease status change, not a single lesion', 'increase.', 'Although a clear progression of ""non-target"" lesions only is exceptional, the opinion of the', 'treating physician should prevail in such circumstances, and the progression status should be', 'confirmed at a later time by the review panel (or Principal Investigator).', '8.2.2.2 Evaluation of Best Overall Response', 'The best overall response is the best response recorded from the start of the treatment until', 'disease progression/recurrence (taking as reference for progressive disease the smallest']"
36,page_37,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '37', 'Version Date: 07/22/2019', ""measurements recorded since the treatment started). The patient's best response assignment will"", 'depend on the achievement of both measurement and confirmation criteria.', 'For Patients with Measurable Disease (i.e., Target Disease)', 'Target', 'Non-Target', 'New', 'Overall', 'Best Overall Response when', 'Lesions', 'Lesions', 'Lesions', 'Response', 'Confirmation is Required*', 'CR', 'CR', 'No', 'CR', '>4 wks. Confirmation**', 'CR', 'Non-', 'No', 'PR', 'CR/Non-PD', 'CR', 'Not', 'No', 'PR', 'evaluated', '>4 wks. Confirmation**', 'PR', 'Non-', 'No', 'PR', 'CR/Non-', 'PD/not', 'evaluated', 'SD', 'Non-', 'No', 'SD', 'CR/Non-', 'Documented at least once >4', 'PD/not', 'wks. from baseline**', 'evaluated', 'PD', 'Any', 'Yes or', 'PD', 'No', 'Any', 'PD***', 'Yes or', 'PD', 'no prior SD, PR or CR', 'No', 'Any', 'Any', 'Yes', 'PD', '*', 'See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.', '**', 'Only for non-randomizedtrials with response as primary endpoint.', 'In exceptional circumstances, unequivocal progression in non-target lesions may be acceptedas', 'disease progression.', 'Note:', 'Patients with a global deterioration of health status requiring discontinuation of treatment without', 'objective evidence of disease progression at that time should be reportedas ""symptomatic', 'deterioration. Every effort should be made to document the objective progression even after', 'discontinuation of treatment.', 'For Patients with Non-Measurable Disease (i.e., Non-Target Disease)', 'Non-TargetLesions', 'New Lesions', 'Overall Response', 'CR', 'No', 'CR', 'Non-CR/non-PD', 'No', 'Non-CR/non-PD', '*', 'Not all evaluated', 'No', 'not evaluated', 'Unequivocal PD', 'Yes or No', 'PD', 'Any', 'Yes', 'PD', '*', '""Non-CR/non-PD is preferred over \'stable disease\' for non-target disease since SD is increasingly used', 'as an endpoint for assessment of efficacy in some trials: so to assign this category when no lesions can be', 'measured is not advised', '8.2.3', 'Duration of Response']"
37,page_38,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '38', 'Version Date: 07/22/2019', 'Duration of overall response: The duration of overall response is measured from the time', 'measurement criteria are met for CR or PR (whichever is first recorded) until the first date that', 'recurrent or progressive disease is objectively documented (taking as reference for progressive', 'disease the smallest measurements recorded since the treatment started).', 'The duration of overall CR is measured from the time measurement criteria are first met for CR', 'until the first date that progressive disease is objectively documented.', 'Duration of stable disease: Stable disease is measured from the start of the treatment until the', 'criteria for progression are met, taking as reference the smallest measurements recorded since the', 'treatment started, including the baseline measurements.', '9', 'ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS', '9.1', 'COMPREHENSIVE ADVERSE Event AND POTENTIAL RISKLIST (CAEPRS)', '9.1.1 Comprehensive Adverse Events and Potential Risks list (CAEPR for SGI-110 (NSC', '780463)', 'The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of', 'reported and/or potential adverse events (AE) associated with an agent using a uniform', 'presentation of events by body system. In addition to the comprehensive list, a subset, the', 'Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and', 'is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are', 'protocol specific exceptions to expedited reporting to NCI (except as noted below). Refer to the', ""'CTEP, NCI Guidelines: Adverse Event Reporting Requirements'"", 'http://ctep.cancer.gov/protocolDevelopment/electronic applications/docs/aeguidelines.pdf for', 'further clarification. Frequency is provided based on 757 patients. Below is the CAEPR for SGI-', '110 (Guadecitabine).', 'NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses next to', 'the AE in the SPEER. If this CAEPR is part of a combination protocol using multiple', 'investigational agents and has an AE listed on different SPEERs, use the lower of the grades to', 'determine if expedited reporting is required.', 'Version 2.1, May 8, 2019¹', 'Adverse Events with Possible', 'Relationship to SGI-110 (Guadecitabine)', 'Specific Protocol', '(CTCAE 5.0 Term)', 'Exceptions to Expedited', '[n= 757]', 'Reporting (SPEER)', 'Rare but Serious', 'Likely (>20%)', 'Less Likely (<=20%)', '(<3%)', 'BLOOD AND LYMPHATIC SYSTEM DISORDERS', 'Anemia', 'Anemia (Gr 2)', 'Febrile neutropenia', 'Febrile neutropenia (Gr 2)', 'EYE DISORDERS']"
38,page_39,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '39', 'Version Date: 07/22/2019', 'Adverse Events with Possible', 'Relations hip to SGI-110 (Guadecitabine)', 'Specific Protocol', '(CTCAE 5.0 Term)', 'Exceptions to Expedited', '[n= 757]', 'Reporting (SPEER)', 'Rare but Serious', 'Likely (>20%)', 'Less Likely (<=20%)', '(<3%)', 'Periorbital edema', 'GASTROINTESTINAL DISORDERS', 'Constipation', 'Constipation (Gr 2)', 'Diarrhea', 'Diarrhea (Gr2)', 'Mucositis oral', 'Mucositis oral (Gr 2)', 'Nausea', 'Nausea (Gr 2)', 'Vomiting', 'Vomiting (Gr 2)', 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS', 'Edema face', 'Fatigue', 'Fatigue (Gr 2)', 'Fever', 'Injection site reaction', 'Injection site reaction (Gr 2)', 'Pain', 'INFECTIONS AND INFESTATIONS', 'Infection²', 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS', 'Bruising', 'Bruising (Gr 1)', 'INVESTIGATIONS', 'Lymphocyte count', 'Lymphocyte count decreased', 'decreased', '(Gr 4)', 'Neutrophil count', 'Neutrophil count decreased', 'decreased', '(Gr 2)', 'Platelet count decreased', 'Platelet count decreased (Gr', '2)', 'White blood cell', 'White blood cell decreased', 'decreased', '(Gr 2)', 'METABOLISM AND NUTRITION DISORDERS', 'Anorexia', 'Anorexia (Gr 2)', 'Tumor lysis syndrome', 'NERVOUS SYSTEM DISORDERS', 'Dizziness', 'Headache', 'PSYCHIATRIC DISORDERS', 'Insomnia', 'RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS']"
39,page_40,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '40', 'Version Date: 07/22/2019', 'Adverse Events with Possible', 'Relations hip to SGI-110 (Guadecitabine)', 'Specific Protocol', '(CTCAE 5.0 Term)', 'Exceptions to Expedited', 'n= 757]', 'Reporting (SPEER)', 'Rare but Serious', 'Likely (>20%)', 'Less Likely (<=20%)', '(<3%)', 'Dyspnea', 'Epistaxis', 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS', 'Purpura', 'Rash maculo-papular', 'This table will be updated as the toxicity profile of the agent is revised. Updates will be distributed', 'to all Principal Investigators at the time of revision. The current version can be obtained by', 'contacting PIO@CTEP.NCI.NIH.GOV. Your name, the name of the investigator, the protocol and', 'the agent should be included in the e-mail.', '2Infection may include any of the 75 infection sites under the INFECTIONS AND INFESTATIONS', 'SOC.', 'Adverse events reported on SGI-110 (Guadecitabine) trials, but for which there is insufficient', 'evidence to suggest that there was a reasonable possibility that SGI-110 (Guadecitabine)', 'caused the adverse event:', 'BLOOD AND LYMPHATIC SYSTEM DISORDERS - Blood and lymphatic system disorders -', 'Other (agranulocytosis); Blood and lymphatic system disorders - Other (coagulopathy); Blood and', 'lymphatic system disorders - Other (febrile bone marrow aplasia); Blood and lymphatic system', 'disorders - Other (histiocytos is hematophagic); Blood and lymphatic system disorders - Other', '(lymphadenopathy); Blood and lymphatic system disorders - Other (pancytopenia); Bone marrow', 'hypocellular; Leukocytosis; Thrombotic thrombocytopenic purpura', 'CARDIAC DISORDERS - Atrial fibrillation; Cardiac disorders - Other (atrial tachycardia);', 'Cardiac disorders - Other (bradycardia); Chest pain - cardiac; Heart failure; Left ventricular systolic', 'dysfunction; Palpitations; Sinus tachycardia', 'CONGENITAL, FAMILIAL AND GENETIC DISORDERS - Congenital, familial and genetic', 'disorders - Other (phimosis)', 'EAR AND LABYRINTH DISORDERS - Ear pain; Vertigo', 'ENDOCRINE DISORDERS - Adrenal insufficiency', 'EYE DISORDERS - Blurred vision; Eye disorders - Other (eye/retinal/conjunctival hemorrhage)', 'GASTROINTESTINAL DISORDERS - Abdominal distension; Abdominal pain; Belching;', 'Cheilitis; Colitis; Dry mouth; Dyspepsia; Dysphagia; Enterocolitis; Esophagitis; Flatulence;', 'Gastritis; Gastroesophageal reflux disease; Gastrointestinal disorders - Other (small intestinal', 'hemorrhage); Gastrointestinal disorders - Other (tongue discoloration); Gastrointestinal pain;']"
40,page_41,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '41', 'Version Date: 07/22/2019', 'Gingival pain; Hemorrhoids; Ileus; Lip pain; Lower gastrointestinal hemorrhage; Oral hemorrhage;', 'Oral pain; Periodontal disease; Rectal hemorrhage; Rectal pain; Small intestinal mucositis; Small', 'intestinal obstruction; Toothache; Typhlitis; Upper gastrointestinal hemorrhage', 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Chills; Edema', 'limbs; Gait disturbance; General disorders and administration site conditions - Other (exercise', 'tolerance decreased); General disorders and administration site conditions - Other (general physical', 'health deterioration); General disorders and administration site conditions - Other (systemic', 'inflammatory response syndrome [SIRS]); Infusion site extravasation; Localized edema; Malaise;', 'Multi-organ failure; Non-cardiac chest pain', 'HEPATOBILIARY DISORDERS - Cholecystitis', 'IMMUNE SYSTEM DISORDERS - Allergic reaction', 'INVESTIGATIONS - Activated partial thromboplastin time prolonged; Alanine aminotransferase', 'increased; Alkaline phosphatase increased; Aspartate aminotransferase increased; Blood bilirubin', 'increased; Creatinine increased; Ejection fraction decreased; Electrocardiogram QT corrected', 'interval prolonged; GGT increased; INR increased; Investigations - Other (elevated c-reactive', 'proteins [c-reactive protein increased]); Investigations - Other (klebsiella test positive);', 'Investigations - Other (reticulocyte count decreased); Investigations - Other (thrombocytosis);', 'Lymphocyte count increased; Weight loss', 'METABOLISM AND NUTRITION DISORDERS - Acidosis; Alkalosis; Dehydration;', 'Hypercalcemia; Hyperglycemia; Hyperkalemia; Hyperphosphatemia; Hyperuricemia;', 'Hypoalbuminemia; Hypocalcemia; Hypoglycemia; Hypokalemia; Hypomagnesemia; Hyponatremia;', 'Hypophosphatemia; Metabolism and nutrition disorders - Other (failure to thrive); Metabolism and', 'nutrition disorders - Other (gout)', 'MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthralgia; Arthritis;', 'Back pain; Bone pain; Flank pain; Generalized muscle weakness; Joint range of motion decreased;', 'Muscle cramp; Musculoskeletal and connective tissue disorder - Other (joint contracture);', 'Musculoskeletal and connective tissue disorder - Other (musculoskeletal stiffness); Musculoskeletal', 'and connective tissue disorder - Other (pain in jaw); Myalgia; Neck pain; Pain in extremity', 'NERVOUS SYSTEM DISORDERS - Ataxia; Dysgeusia; Lethargy; Paresthesia; Presyncope;', 'Syncope', 'PSYCHIATRIC DISORDERS - Anxiety; Delirium; Depression', 'RENAL AND URINARY DISORDERS - Acute kidney injury; Hematuria; Urinary frequency;', 'Urinary tract pain; Urinary urgency', 'REPRODUCTIVE SYSTEM AND BREAST DISORDERS - Penile pain; Vaginal hemorrhage', 'RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Adult respiratory distress', 'syndrome; Atelectasis; Bronchopulmonary hemorrhage; Cough; Hypoxia; Nasal congestion;', 'Oropharyngeal pain; Pleural effusion; Pleuritic pain; Pneumonitis; Respiratory failure; Respiratory,', 'thoracic and mediastinal disorders - Other (oropharyngeal blistering); Rhinorrhea; Sneezing;', 'Wheezing', 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Alopecia; Bullous dermatitis; Dry skin;', 'Hyperhidrosis; Lipohypertrophy; Pruritus; Rash acneiform; Skin and subcutaneous tissue disorders -']"
41,page_42,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '42', 'Version Date: 07/22/2019', 'Other (dermal cyst); Skin and subcutaneous tissue disorders - Other (granuloma annulare); Skin and', 'subcutaneous tissue disorders - Other (onychoclasis); Skin induration; Skin ulceration', 'VASCULAR DISORDERS - Hematoma; Hot flashes; Hypertension; Hypotension;', 'Thromboembolic event', 'Note: SGI-110 (Guadecitabine) in combination with other agents could cause an exacerbation of any', 'adverse event currently known to be caused by the other agent, or the combination may result in', 'events never previously associated with either agent.', '9.2 ADVERSE Event CHARACTERISTICS', 'CTCAE term (AE description) and grade: The descriptions and grading scales found', 'in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version', '5.0 will be utilized for AE reporting. All appropriate treatment areas should have access', 'to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be', 'downloaded from the CTEP website', 'http://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm.', 'For expedited reporting purposes only:', '-', 'AEs for the agent that are bold and italicized in the CAEPR (i.e., those listed in the', 'SPEER column, Section 9.1.1) should be reported through CTEP-AERS only if the', 'grade is above the grade provided in the SPEER.', '-', 'Other AEs for the protocol that do not require expedited reporting are outlined in', 'section 9.3.3.', 'Attribution of the AE:', '-', 'Definite - The AE is clearly related to the study treatment.', '-', 'Probable - The AE is likely related to the study treatment.', '-', 'Possible - The AE may be related to the study treatment.', '-', 'Unlikely - The AE is doubtfully related to the study treatment.', '-', 'Unrelated - The AE is clearly NOTrelated to the study treatment.', '9.3 EXPEDITED ADVERSE Event REPORTING TO CTEP', '9.3.1 Expedited AE reporting', 'Expedited AE reporting for this study must use CTEP-AERS (CTEP Adverse Event Reporting', 'System), accessed via the CTEP website (https://eapps-ctep.nci.nih.gov/ctepaers). The reporting', 'procedures to be followed are presented in the ""NCI Guidelines for Investigators: Adverse Event', 'Reporting Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs"" which can be', 'downloaded from the CTEP website', ' (http://ctep.cancer.gov/protocolDevelopment/electronic: applications/adverse events.htm).', 'These requirements are briefly outlined in the tables below (Section 9.3.3).', 'In the rare occurrence when Internet connectivity is lost, a 24-hour notification is to be made to', 'CTEP by telephone at 301-897-7497. Once Internet connectivity is restored, the 24-hour']"
42,page_43,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '43', 'Version Date: 07/22/2019', 'notification phoned in must be entered electronically into CTEP-AERS by the original submitter', 'at the site.', '9.3.2 Distribution of Adverse Event Reports', 'CTEP-AERS is programmed for automatic electronic distribution of reports to the following', 'individuals: Principal Investigator and Adverse Event Coordinator(s) (if applicable) of the', 'Corresponding Organization or Lead Organization, the local treating physician, and the Reporter', 'and Submitter. CTEP-AERS provides a copy feature for other e-mail recipients.', '9.3.3 Expedited Reporting Guidelines', 'Use the NCI protocol number and the protocol-specific patient ID assigned during trial', 'registration on all reports.', 'Note: A death on study requires both routine and expedited reporting, regardless of', 'causality. Attribution to treatment or other cause must be provided.', 'Death due to progressive disease should be reported as Grade 5 ""Disease progression"" in the', 'system organ class (SOC) ""General disorders and administration site conditions."" Evidence that', 'the death was a manifestation of underlying disease (e.g., radiological changes suggesting tumor', 'growth or progression: clinical deterioration associated with a disease process) should be', 'submitted.', 'Phase 1 and Early Phase 2 Studies: Expedited Reporting Requirements for Adverse', 'Events that Occur on Studies under an IND/IDE within 30 Days of the Last Administration', 'of the Investigational Agent/Intervention 1,2', 'FDA REPORTING REQUIREMENTS FOR SERIO US ADVERSE EVENTS (21 CFR Part 312)', 'NOTE: Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not they are', 'considered relatedto the investigational agent(s)/intervention (21 CFR 312.64)', 'An adverse event is considered serious if it results in ANY of the following outcomes:', '1) Death', '2) A life-threatening adverse event', '3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for> 24 hours', '4)', 'A', 'persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions', '5) A congenital anomaly/birth defect.', '6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be', 'considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require', 'medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH', 'E2A and ICH E6).', 'ALL SERIO US adverse events that meet the above criteria MUST be immediately reported to the NCI via AdEERS within', 'the timeframes detailed in the table below.', 'Grade 3-5', 'Hospitalization', 'Grade 1 and Grade 2 Timeframes', 'Timeframes']"
43,page_44,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '44', 'Version Date: 07/22/2019', 'Resulting in', 'Hospitalization >', '10 Calendar Days', '24 hrs', '24-Hour 5 Calendar Days', 'Not resulting in', 'Hospitalization >', 'Not required', '24 hrs', 'NOTE: Protocol-specific exceptions to expedited reporting of serious adverse events are found in the Specific Protocol', 'Exceptions to Expedited Reporting (SPEER) portion of the CAEPR.', 'Expedited AE reporting timelines are de fined as:', '""24-Hour; 5 Calendar Days"" - The AE must initially be reported via AdEERS within 24 hours of learning of the', 'AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report.', '""10 Calendar Days"" - A complete expedited report on the AE must be submitted within 10 calendar days of', 'learning of the AE.', '1Serious adverse events that occur more than 30 days after the last administration of investigational agent/intervention', 'and have an attribution of possible, probable, or definite require reporting as follows:', 'Expedited 24-hour notification followed by complete report within 5 calendar days for:', 'All Grade 3, 4, and Grade 5 AEs', 'Expedited 10 calendar day reports for:', 'Grade 2 AEs resulting in hospitalization or prolongation of hospitalization', '2 For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half-lives, rounded', 'UP to the nearest whole day, after the agent/intervention was last administered. Footnote ""1"" above applies after this', 'reporting period.', 'Effective Date: May 5, 2011', '9.4 ROUTINE ADVERSE Event REPORTING TO CTEP', 'All Adverse Events must be reported in routine study data submissions. AEs reported', 'expeditiously through CTEP-AERS must also be reported in routine study data', 'submissions.', '9.5 SECONDARY MALIGNANCY', 'A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g.,', 'treatment with investigational agent/intervention, radiation or chemotherapy). A secondary', 'malignancy is not considered a metastasis of the initial neoplasm.', 'CTEP requires all secondary malignancies that occur following treatment with an agent under an', 'NCI IND/IDE be reported via CTEP-AERS. Three options are available to describe the event:', 'Leukemia secondary to oncology chemotherapy (e.g., acute myelocytic leukemia [AML])', 'Myelodysplastic syndrome (MDS)', 'Treatment-related secondary malignancy', 'Any malignancy possibly related to cancer treatment (including AML/MDS) should also be', 'reported via the routine reporting mechanisms outlined in each protocol.']"
44,page_45,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '45', 'Version Date: 07/22/2019', '9.6 SECOND MALIGNANCY', 'A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a', 'metastasis from the initial malignancy). Second malignancies require ONLY routine reporting', 'unless otherwise specified.', '10 NIH INTRAMURAL RESEARCH PROGRAM REPORTING', '10.1 DEFINITIONS', 'Please refer to definitions provided in Policy 801: Reporting Research Events found here.', '10.2 OHSRP OFFICE OF COMPLIANCE AND TRAINING/ IRB REPORTING', '10.2.1 Expedited Reporting', 'Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy', '802 Non-Compliance Human Subjects Research found here. Note: Only IND Safety Reports that', 'meet the definition of an unanticipated problem will need to be reported per these policies.', '10.2.2 IRB Requirements for PI Reporting at Continuing Review', 'Please refer to the reporting requirements in Policy 801: Reporting Research Events found here.', '10.3 NCICLINICAL DIRECTOR REPORTING', 'Problems expeditiously reported to the OHSRP/IRB in iRIS will also be reported to the NCI', 'Clinical Director. A separate submission is not necessary as reports in iRIS will be available to', 'the Clinical Director.', 'In addition to those reports, all deaths that occur within 30 days after receiving a research', 'intervention should be reported via email to the Clinical Director unless they are due to', 'progressive disease.', 'To report these deaths, please send an email describing the circumstances of the death to Dr.', 'Dahut at NCICCRQA@mail.nih.gov within one business day of learning of the death.', '11 STUDY OVERSIGHT AND DATA REPORTING/REGULATORY', 'REQUIREMENTS', '11.1 STUDY OVERSIGHT', 'This protocol is monitored at several levels, as described elsewhere in this section. The Protocol', 'Principal Investigator is responsible for monitoring the conduct and progress of the clinical trial,', 'including the ongoing review of accrual, patient-specific clinical and laboratory data, and routine', 'and serious adverse events; reporting of expedited adverse events; and accumulation of reported', 'adverse events from other trials testing the same drug(s). The Protocol Principal Investigator and', 'statistician have access to the data at all times.']"
45,page_46,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '46', 'Version Date: 07/22/2019', 'All Study Investigators at participating sites who register/enroll patients on a given protocol are', 'responsible for timely submission of data via the mechanism described elsewhere in this section.', ""All studies are also reviewed in accordance with the enrolling institution's data safety monitoring"", 'plan.', 'End of study procedures: Data will be stored according to HHS, FDA regulations, and NIH', 'Intramural Records Retention Schedule as applicable.', 'Loss or destruction of data: Should we become aware that a major breach in our plan to protect', 'subject confidentiality and trial data has occurred, this will be reported expeditiously per', 'requirements in section 10.2.1.', '11.2 DATA REPORTING', 'Data collection for this study will be done exclusively through Medidata Rave. Access to the', 'trial in Rave is granted through the iMedidata application to all persons with the appropriate', 'roles assigned in the Regulatory Support System (RSS). To access Rave via iMedidata, the site', 'user must have an active CTEP IAM account (https://eapps-ctep.nci.nih.gov/iam) and the', 'appropriate Rave role (Rave CRA, Read-Only, or Site Investigator) on either the Corresponding', 'Organization or Participating Organization roster at the enrolling site.', 'Upon initial site registration approval for the study in RSS, all persons with Rave roles assigned', 'on the appropriate roster will be sent a study invitation e-mail from iMedidata. To accept the', 'invitation, site users must log into the Select Login (https://login.imedidata.com/selectlogin', 'using their CTEP-IAM user name and password, and click on the ""accept"" link in the upper', 'right-corner of the iMedidata page. Please note, site users will not be able to access the study in', 'Rave until all required Medidata and study specific trainings are completed. Trainings will be in', 'the form of electronic learnings (eLearnings), and can be accessed by clicking on the link in the', 'upper right pane of the iMedidata screen.', 'Users that have not previously activated their Medidata/Rave account at the time of initial site', 'registration approval for the study in RSS will also receive a separate invitation from iMedidata', 'to activate their account. Account activation instructions are located on the CTSU website, Rave', 'tab under the Rave resource materials (Medidata Account Activation and Study Invitation', ""Acceptance). Additional information on iMedidata/Rave is available on the CTSU members'"", 'website under the Rave tab or by contacting the CTSU Help Desk at 1-888-823-5923 or by e-', 'mail at ctsucontact@westat.com.', '11.2.1 Method', 'This study will be monitored by the Clinical Trials Monitoring Service (CTMS). Data will be', 'submitted to CTMS at least once every two weeks via Medidata Rave (or other modality if', 'approved by CTEP). Information on CTMS reporting is available at:', '  http://www.theradex.com/clinicalTechnologies/?National-Cancer-Institute-NCI-1 On-site', 'audits will be conducted on an 18-36 month basis as part of routine cancer center site visits.', 'More frequent audits may be conducted if warranted by accrual or due to concerns regarding', 'data quality or timely submission. For CTMS monitored studies, after users have activated their', 'accounts, please contact the Theradex Help Desk at (609) 799-7580 or by email at', 'CTMSSupport@theradex.com for additional support with Rave and completion of CRFs.']"
46,page_47,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '47', 'Version Date: 07/22/2019', '11.3 DATA SHARING PLANS', '11.3.1 Human Data Sharing Plan', 'I', 'will share coded, linked human data generated in this research for future research in a NIH-', 'funded or approved public repository at the time of publication or shortly thereafter.', '11.3.2 Genomic Data Sharing Plan', 'Unlinked genomic data will be deposited in public genomic databases such as dbGaP in', 'compliance with the NIH Genomic Data Sharing Policy', '12 STATISTICAL CONSIDERATIONS', 'SGI-110 activity will be assessed by radiographic response of measurable disease using', 'RECISTv1.1 The study will be conducted as a small, optimal two-stage phase II trial40, in order', 'to rule out an unacceptably low 5% overall response rate (ORR; p0=0.05), in favor of a slightly', 'higher response rate of 30% (p1=0.30). With alpha=0.10 (probability of accepting a poor', 'treatment=0.10) and beta = 0.10 (probability of rejecting a good treatment=0.10), the study will', 'initially enroll 7 evaluable patients in each group (strata) and if 0 of the 7 have a response, then', 'no further patients will be accrued in that stratum. If 1 or more the first 7 (14.3.1% or more) have', 'a response, then accrual would continue until a total of 21 patients have enrolled in that stratum.', 'Only complete responses (CR) and partial responses (PR) will be counted towards the overall', 'response rate. As it may take several weeks to months to determine if a patient has experienced', 'a response, a temporary pause in the accrual to that stratum in the trial may be necessary to', 'ensure that enrollment to the second stage is warranted. If there are 1 to 2 responses in 21', 'patients, this would be an uninterestingly low response rate, while if there were 3 or more', 'responses in 21 (14.3% or more) patients, then this would be sufficiently interesting to warrant', 'further study in later trials. Under the null hypothesis (5% response rate), the probability of early', 'termination is 70%. With three cohorts of up to 21 patients apiece, the maximum number of', 'evaluable patients required would be 63. In order to allow for a small number of inevaluable', 'patients, the accrual ceiling will be set to 70.', 'Descriptive summaries of the secondary outcome variables (toxicity, progression-free survival,', 'overall survival, quality of life, pharmacokinetics, pharmacodynamics) will be presented at the', 'time of the primary analysis, and will be repeated in subsequent analyses to characterize the', 'extent to which changes are maintained over a longer follow-up period. Each of these secondary', 'endpoints will be assessed in a hypothesis generating manner, without formal adjustment for', 'multiple comparisons but reported in the context of the number and type of evaluation being', 'performed.', 'In addition, progression-free survival and overall survival will be reported separately for each', 'stratum. Changes in QOL will be evaluated relative to any degree of response and summary', 'statistics will be described over time. As these evaluations may be performed in a post hoc', 'manner based on the response results obtained, the findings will need to be carefully presented in', 'the context of the exploratory nature of the analyses undertaken.']"
47,page_48,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '48', 'Version Date: 07/22/2019', '13 COLLABORATIVE AGREEMENTS', 'The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI', 'under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical', 'Company(ies) (hereinafter referred to as ""Collaborator(s)"") and the NCI Division of Cancer', 'Treatment and Diagnosis. Therefore, the following obligations/guide lines in addition to the', 'provisions in the ""Intellectual Property Option to Collaborator""', '(http://ctep.cancer.gov/industryCollaborations2/intellectual property.htm) contained within the', 'terms of award, apply to the use of the Agent(s) in this study:', '1.', 'Agent(s) may not be used for any purpose outside the scope of this protocol, nor can', 'Agent(s) be transferred or licensed to any party not participating in the clinical study.', 'Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and shall', 'be maintained as such by the investigators. The protocol documents for studies utilizing', 'Agents contain confidential information and should not be shared or distributed without the', ""permission of the NCI. If a copy of this protocol is requested by a patient or patient's family"", 'member participating on the study, the individual should sign a confidentiality agreement. A', 'suitable model agreement can be downloaded from: http://ctep.cancer.gov.', '2. For a clinical protocol where there is an investigational Agent used in combination with', '(an)other Agent(s), each the subject of different Collaborative Agreements, the access to and', 'use of data by each Collaborator shall be as follows (data pertaining to such combination use', 'shall hereinafter be referred to as ""Multi-Party Data""):', 'a. NCI will provide all Collaborators with prior written notice regarding the existence and', 'nature of any agreements governing their collaboration with NCI, the design of the', 'proposed combination protocol, and the existence of any obligations that would tend to', ""restrict NCI's participation in the proposed combination protocol."", 'b. Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial', 'by any other Collaborator solely to the extent necessary to allow said other Collaborator', 'to develop, obtain regulatory approval or commercialize its own Agent.', 'c.', 'Any Collaborator having the right to use the Multi-Party Data from these trials must', 'agree in writing prior to the commencement of the trials that it will use the Multi-Party', 'Data solely for development, regulatory approval, and commercialization of its own', 'Agent.', '3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement', 'will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless', 'additional disclosure is required by law or court order as described in the IP Option to', 'Collaborator (http://ctep.cancer.gov/industryCollaborations2/intellectual property.htm).', 'Additionally, all Clinical Data and Results and Raw Data will be collected, used and', 'disclosed consistent with all applicable federal statutes and regulations for the protection of', 'human subjects, including, if applicable, the Standards for Privacy of Individually', 'Identifiable Health Information set forth in 45 C.F.R. Part 164.', '4. When a Collaborator wishes to initiate a data request, the request should first be sent to the', 'NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group', ""studies, or PI for other studies) of Collaborator's wish to contact them.""]"
48,page_49,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '49', 'Version Date: 07/22/2019', '5. Any data provided to Collaborator(s) for Phase 3 studies must be in accordance with the', 'guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a', 'DMC for this clinical trial.', '6. Any manuscripts reporting the results of this clinical trial must be provided to CTEP by the', 'Group office for Cooperative Group studies or by the principal investigator for non-', 'Cooperative Group studies for immediate delivery to Collaborator(s) for advisory review and', 'comment prior to submission for publication. Collaborator(s) will have 30 days from the', 'date of receipt for review. Collaborator shall have the right to request that publication be', ""delayed for up to an additional 30 days in order to ensure that Collaborator's confidential and"", ""proprietary data, in addition to Collaborator(s)'s intellectual property rights, are protected."", 'Copies of abstracts must be provided to CTEP for forwarding to Collaborator(s) for courtesy', 'review as soon as possible and preferably at least three (3) days prior to submission, but in', 'any case, prior to presentation at the meeting or publication in the proceedings. Press', 'releases and other media presentations must also be forwarded to CTEP prior to release.', 'Copies of any manuscript, abstract and/or press release/ media presentation should be sent to:', 'Email: ncicteppubs@mail.nih.gov', 'The Regulatory Affairs Branch will then distribute them to Collaborator(s). No publication,', ""manuscript or other form of public disclosure shall contain any of Collaborator's confidential/"", 'proprietary information.', '14 HUMAN SUBJECTS PROTECTIONS', '14.1 RATIONALE FOR SUBJECT SELECTION', 'Patients of both genders, from all racial and ethnic groups are eligible for this trial if they meet the', 'eligibility criteria outlined in Section 3.1. There is no clinical information that suggests differences', 'in SGI-110 metabolism or response among racial or ethnic groups or between the genders,', 'indicating that results of the trial will be applicable to all groups. This phase II trial of SGI-110', 'will be conducted in children greater than or equal to 12 years of age and adults measurable,', 'localized or metastatic or unresectable wild-type GIST, SDH deficient PHEO/PGL, or HLRCC-', 'associated RCC will be eligible for trial participation. Patients with PHEO/PGL or RCC must', 'have recurrent or refractory disease. Efforts will be made to extend the accrual to a representative', 'group from this population, but with these uncommon diseases and with a planned accrual of 24', 'patients, a balance must be struck between completing the trial in a timely fashion on the one hand', 'and the need to explore gender, racial, and ethnic aspects of clinical research on the other. If', 'differences in outcome that correlate to gender, racial, or ethnic identity are noted, accrual may be', 'expanded or additional studies may be performed to investigate those differences more fully.', '14.1.1', 'Gender and Minority Accrual Estimates', 'DOMESTIC PLANNED ENROLLMENT REPORT', 'Ethnic Categories', 'Racial', 'Categories', 'Not Hispanic or Latino', 'Hispanic or Latino', 'Total', 'Female', 'Male', 'Female', 'Male']"
49,page_50,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '50', 'Version Date: 07/22/2019', 'DOMESTIC PLANNED ENROLLMENT REPORT', 'American', '1', '1', '2', 'Indian/ Alaska', 'Native', 'Asian', '1', '3', '4', 'Native', '0', '0', '0', 'Hawaiian or', 'Other Pacific', 'Islander', 'Black or', '4', '5', '9', 'African', 'American', 'White', '22', '25', '3', '4', '54', 'More Than One', '1', '1', 'Race', 'Total', '29', '34', '3', '4', '70', '14.2 PARTICIPATION OF CHILDREN', 'Children greater than or equal to 12 years of age will be eligible and the drugs pharmacokinetics', 'will be explored in this age group. The safety of SGI-110 has not been established in children', 'and therefore younger age groups will be excluded until more safety data is available in this age', 'group. Children greater than or equal to 12 years of age will be enrolled and the study will be', 'conducted by pediatric oncologists who have extensive experience in performing investigational', 'drug trials in children. Patients enrolled at the POB, NCI will be cared for in the POB outpatient', 'clinic or day hospital. When patients require hospital admission, they will be cared for on the', '1NW Pediatric Unit by the POB staff.', '14.3 PARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT', 'Adults unable to give consent are excluded from enrolling in the protocol. However, re-consent', 'may be necessary and there is a possibility, though unlikely, that subjects could become', 'decisionally impaired. For this reason and because there is a prospect of direct benefit from', 'research participation (section 14.5), all subjects > age 18 will be offered the opportunity to fill', 'in their wishes for research and care, and assign a substitute decision maker on the ""NIH', 'Advance Directive for Health Care and Medical Research Participation"" form so that another', 'person can make decisions about their medical care in the event that they become incapacitated', 'or cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH', 'Ability to Consent Assessment Team (ACAT) for evaluation as needed for the following: an', 'independent assessment of whether an individual has the capacity to provide consent; assistance', 'in identifying and assessing an appropriate surrogate when indicated; and/or an assessment of the', 'capacity to appoint a surrogate. For those subjects that become incapacitated and do not have', 'pre-determined substitute decision maker, the procedures described in NIH HRPP SOP1 14E for']"
50,page_51,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '51', 'Version Date: 07/22/2019', 'appointing a surrogate decision maker for adult subjects who are (a) decisionally impaired, and', '(b) who do not have a legal guardian or durable power of attorney, will be followed.', '14.4 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS', '14.4.1 Risks of SGI-110', 'The primary risk to patients participating in this research study is from toxicity of SGI-110. In', 'adults, SGI-110 has been relatively well tolerated. The dose limiting toxicities observed with', 'SGI-110 include grade 4 neutropenia and thrombocytopenia and grade 5 sepsis. The most', 'common toxicities reported with SGI-110 monotherapy include neutropenia, thrombocytopenia,', 'fatigue, diarrhea, injection site pain (including pain, burning, irritation, erythema, inflammation,', 'bleeding, pain, or subcutaneous nodules), anemia, febrile neutropenia (See Section 9.1).', '14.5 RISKS/BENEFITS ANALYSIS', 'Gastrointestinal stromal tumors (GISTs) are resistant to cytotoxic chemotherapy and radiation', 'therapy. KIT and PDGFRA mutations have been identified as tumor initiating events in 85% of', 'adult patients with GIST and these tumors are responsive to the tyrosine kinase inhibitor,', 'Imatinib. In pediatric patients, however, 85% of GISTs lack KIT and PDGFRA mutations (wild-', 'type) and imatinib is not effective. SDH deficiency is present in the majority of patients with wt-', 'GIST and guadecitabine may have activity in this population of patients.', 'Approximately 10-30% of PHEO/PGL are SDH-deficient13,14 and there is an increased risk', 'of', 'more aggressive metastatic disease in patients with SDHB mutation. Surgical resection is the', 'only curative therapy for patients with PHEO/PGL, however both radiation therapy and', 'cytotoxic chemotherapy using cyclophosphamide, vincristine, and dacarbazine (CVD) have been', 'used to treat patients with metastatic or recurrent disease 12 While responses can be seen with', 'this', 'therapy, complete durable responses are rare and additional therapeutic options are lacking.', 'Guadecitabine may have activity in this population of patients with SDH-deficient PHEO/PGL.', 'HLRCC-associated kidney cancer is typically clinically aggressive with early development of', 'metastatic disease. Nephron-sparing surgical therapy is standard for localized HLRCC-associated', 'renal cancer22. While there is currently no standard systemic therapy for metastatic HLRCC-', 'associated renal cell cancer, treatments targeting the VEGF and EGFR pathways are being', 'investigated in ongoing clinical trials22 HLRCC is an autosomal-dominant hereditary syndrome', 'due to mutations in FH5.', 'All three of these tumors (SDH deficient PHEO/PGL, HLRCC-associated RCC, and wt-GIST)', 'have limited treatment options for metastatic and locally recurrent disease and are associated', 'with deficiency in the Krebs cycle components SDH and FH. These tumors exhibit global DNA', 'hypermethylation and may be responsive to guadecitabine. Therefore, this phase II protocol', 'involves greater than minimal risk to children, but presents the prospect for direct benefit to', 'individual child-subjects (Category 2).', '14.6 CONSENTAND ASSENT PROCESS AND DOCUMENTATION', 'The procedures and tests involved in this study and the associated risks, discomforts and benefits', ""of these processes, will be carefully explained to the patient or the patient's parents or guardian if""]"
51,page_52,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '52', 'Version Date: 07/22/2019', 'he/she is a child, and a signed informed consent document will be obtained prior to entry onto', 'the study.', 'The investigators are requesting a waiver from the IRB to allow only one parent to sign the', 'treatment informed consent form to enter a child on the protocol. Because many patients must', 'travel to the NIH from long distances at substantial expense, requiring both parents to be present', 'for the consent process could be a financial hardship for many families. The parent who signs', 'the consent for a minor must be a legally recognized parent or guardian. When guardianship', 'status of the child is uncertain, documentation of custody status must be obtained.', 'In situations where there is joint custody of a child, both parents must sign consent. If only one', ""parent can be present at NIH, the other parent's consent can be obtained by telephone via the"", 'procedure described in section 14.6.1.', ""Where deemed appropriate by the clinician and the child's parent(s) or guardian, the child will"", 'also be included in all discussions about the trial and age-appropriate language will be used to', 'describe the procedures and tests involved in this study, along with the risks, discomforts and', 'benefits of participation. Verbal assent will be obtained as appropriate for children ages 7-11', 'and the parent or guardian will sign the designated line on the informed consent attesting to the', 'fact that the child has given assent. Children under the age of 18, but who are age 12 or older', 'will be asked to sign an age appropriate assent form. Children under the age of 12 will not be', 'required to provide assent as they typically do not have the cognitive ability to fully understand', ""the nature of research. The consent/assent process will be documented in the child's medical"", ""record, including the assessment of the child's ability to provide assent (verbal versus written) as"", 'applicable.', '14.6.1 Consent for minors when they reach the age of majority', 'When a pediatric subject reaches age 18, continued participation (including ongoing interactions', 'with the subject or continued analysis of identifiable data) will require consenting of the now', 'adult with the standard protocol consent document to ensure legally effective informed consent', 'has been obtained. Given the length of time that has transpired for some of the subjects since', 'their last visit for this study, we request waiver of informed consent for those individual ls who', 'become lost to follow up or who have been taken off study prior to reaching the age of majority.', 'Requirements for Waiver of Consent consistent with 45 CFR 46.116 (d):', '(1) The research involves no more than minimal risk to the subjects.', 'a. Analysis of samples and data from this study involves no additional risks to', 'subjects.', '(2) The waiver or alteration will not adversely affect the rights and welfare of the', 'subjects.', 'a. Retention of these samples or data does not affect the welfare of subjects.', '(3) The research could not practicably be carried out without the waiver or alteration.', ""a. Considering the length of time between the minor's last contact with the"", 'research team and their age of majority, it will likely be very difficult to locate', 'them again. A significant reduction in the number of samples analyzed is', 'likely to impact the quality of the research.']"
52,page_53,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '53', 'Version Date: 07/22/2019', '(4) Whenever appropriate, the subjects will be provided with additional pertinent', 'information after participation.', 'a. We only plan to request a waiver of reconsent for those subjects who have', 'been lost to follow-up', '14.6.2 Telephone consent', 'The following procedure may be used in cases where reconsent is required. This process may', 'also be used to obtain initial consent of an absent parent when both parental signatures are', 'required. The informed consent document will be sent to the subject. An explanation of the', 'study will be provided over the telephone after the subject has had the opportunity to read the', 'consent form. The subject will sign and date the informed consent.', 'The original informed consent document will be sent back to the consenting investigator who', 'will sign and date the consent form with the date the consent was obtained via telephone.', ""A fully executed copy will be returned via mail for the subject's records."", 'The informed consent process will be documented in the medical record.', '15 PHARMACEUTICAL INFORMATION', '15.1 SGI-110 (GUADECITABINE) (NSC 780463)', 'Chemical Name or Amino Acid Sequence:', 'Sodium (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-y1)-2-(hydroxymethyl)', 'tetrahydrofuran-3-yl ((2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-y1)-3', 'hydroxytetrahydrofuran-2-yl)methyl phosphate', 'Other Names: Guadecitabine', 'Classification: DNA methylation inhibitor', 'Molecular Formula: C18H23N9NaO10P', 'M.W.: 579.39 Da', 'Approximate Solubility: It is water soluble at about 30 mg/mL over a pH range of 6.0 to 7.0. It', 'is unstable in aqueous solutions and is relatively more stable at neutral pH. SGI-110 is soluble in', 'common organic solvent systems such as methanol, dimethylamine (DMA), and dimethyl', 'sulfoxide (DMSO).', 'Mode of Action: Guadecitabine (SGI-110) is a potent inhibitor of DNA methylation.', 'Guadecitabine is a dinucleotide of decitabine and deoxyguanosine linked with a phosphodiester', 'bond. Decitabine is the active metabolite. Guadecitabine is a new chemical entity that was', 'designed to enhance pharmacokinetic (PK) properties compared with decitabine, with potential', 'to improve pharmacodynamics (PD), clinical efficacy, and safety.', 'How Supplied SGI-110 for Injection is supplied by Astex Pharmaceutical and distributed by the', 'Pharmaceutical Management Branch, CTEP/DCTD/NCI as follow:', 'SGI-110 for Injection: 100 mg dry powder lyophile containing free acid equivalent in a', 'single-use vial;']"
53,page_54,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '54', 'Version Date: 07/22/2019', 'Diluents for Reconstitution: Two fill volumes: 3 mL or 1.2 mL', '3 mL single-use vial containing non-aqueous diluent of propylene glycol, glycerin,', 'and ethanol. (Will be phased out around July 2019)', '1.2 mL single-use vial containing non-aqueous diluent of propylene glycol,', 'glycerin, and ethanol. (Will be available for use around July 2019)', 'All vials are packaged in clear glass vials with stoppers made of latex-free rubber stopper and', 'capped with an aluminum flip-off seal.', 'Preparation:', '1. Allow SGI-110 vial(s) and diluent vial(s) to reach room temperature approximately 60', 'minutes.', '2. Next, loosen the lyophilized powder of SGI-110 by gently tapping and rotating the vial on a', 'hard surface.', '3. Use a 1 mL syringe and withdraw 0.9 mL of diluent and add it to the SGI-110 vial resulting', 'in a final concentration of 100 mg/mL. Manually shake or mechanically vortex the diluted', 'vial(s).', 'Manually shake: Intermittently shake the reconstituted vial vigorously', '(approximately 5 minutes). In general, the shaking process will take 5 to 10', 'minutes. Rotate the vial and inspect the vial contents to ensure that all lyophilized', 'SGI-110 powder has dissolved. After dissolution, allow the vial to rest until all', 'bubbles have dissipated (approximately 10 minutes).', 'Mechanically shake (vortex): Before vortexing, rotate or shake the vial to ensure', 'that the drug powder is thoroughly wetted with diluent. Then, vortex for 5-10', 'minutes at a speed setting of 5. Remove the vial from the holder and invert it 2-3', 'times. Place the vial on the vortex and mix for another 10 minutes. Ensure that all', 'SGI-110 powder is completely dissolved. Repeat the process if partially', 'dissolved. Once all drug is dissolved, allow the solution rest until all bubbles', 'dissipate (approximately 10 minutes).', '4. The final solution of the diluted vial should be colorless to pale yellow.', '5. Withdraw the diluted solution into a syringe. If two or more syringes are needed to deliver', 'the total prescribed dose, all dispensed syringes should have equivalent volumes for', 'consistency and ease of administration.', 'Note: If SGI-110 powder has not dissolved 60 minutes after completion of manually shaking or', 'vortex, do not use the vial(s).', 'Vortex: Sites that do not have access to a vortex may request it directly from Astex', 'Pharmaceuticals, Inc.', 'Contact: Richard Morishige', 'Phone: (925) 560-2882', 'Email: Richard.Morishige@astx.com', 'Storage:', 'Store SGI-110 lyophilized powder refrigerated between 2° and 80 C (360 and 46°F)']"
54,page_55,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '55', 'Version Date: 07/22/2019', 'Store 3 mL diluent between 2° and 30° C (360 F and 86°F)', 'Store 1.2 mL diluent between 2° and 80 C (360 and 460 F)', 'If a storage temperature excursion is identified, promptly return SGI-110 vials and the diluents to', 'the recommended storage temperatures above and quarantine the supplies. Provide a detailed', 'report of the excursion (including documentation of temperature monitoring and duration of the', 'excursion) to PMBAfterHours@mail.nih.goy for determination of suitability.', 'Stability: Stability studies of SGI-110 intact vials are ongoing.', 'Upon reconstitution, the diluted drug solution is good for 8 days refrigerated at 2 to 8 C', 'Route(s) of Adminis tration: subcutaneous injection', 'Method of Adminis tration: Administer by slow subcutaneous injection. Care must be taken to', 'avoid intradermal injection. If injection site pain is reported upon injection, apply ice packs to the', 'injection site both before and after injection for 5 - 10 minutes each; however, using icepack for the', 'first dosing is not recommended. Pretreatment of topical or systemic analgesics can be considered.', 'Potential Drug Interactions: Drug-drug interaction studies have not been conducted with', 'guadecitabine or decitabine. In vitro studies suggested that guadecitabine is unlikely to inhibit or', 'induce major P450 enzymes and is not a CYPs substrate. Furthermore, guadecitabine nor the active', 'metabolite decitabine inhibit major human drug transporters.', 'Special Handling: SGI-110 is a cytotoxic agent. Use PPE when preparing the drug. Direct contact', 'of SGI-110 to skin must be washed immediately with soap and copious amount of water. The drug', 'degrades rapidly in soap water. IfSGI-110 contacts the mucous membranes, flush the affected area', 'thoroughly with water.', 'Drug spilling can be inactivated by either using a 2 N sodium hydroxide solution or water and', 'kericide CR Biocide B which consists of a blend of stabilized chlorine dioxide and a quaternary', 'ammonium compound', '15.1.1 Agent Ordering and Agent Accountability:', 'Active CTEP-registered investigators and investigator-designated shipping designees and', 'ordering designees can submit agent requests through the PMB Online Agent Order Processing', '(OAOP) application Access to OAOP requires the establishment of a CTEP Identity and Access', 'Management (IAM) account and the maintenance of an ""active"" account status and a ""current""', 'password. For questions about drug orders, transfers, returns, or accountability, call or email', ""PMB any time. Refer to the PMB's website for specific policies and guidelines related to agent"", 'management.', 'Agent Inventory Records - The investigator, or a responsible party designated by the', 'investigator, must maintain a careful record of the receipt, dispensing and final disposition of all', 'agents received from the PMB using the appropriate NCI Investigational Agent (Drug)', 'Accountability Record (DARF) available on the CTEP forms page. Store and maintain separate', 'NCI Investigational Agent Accountability Records for each agent, strength, formulation and', 'ordering investigator on this protocol.', 'Investigator Brochure Availability - The current versions of the IBs for the agents will be', 'accessible to site investigators and research staff through the PMB Online Agent Order']"
55,page_56,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '56', 'Version Date: 07/22/2019', 'Processing (OAOP) application. Access to OAOP requires the establishment of a CTEP Identity', 'and Access Management (IAM) account and the maintenance of an ""active"" account status and', 'a', '""current"" password. Questions about IB access may be directed to the PMB IB coordinator via', 'email.', 'Useful Links and Contacts:', 'CTEP Forms, Templates, Documents: http://ctep.cancer.gov/forms/', 'NCI CTEP Investigator Registration: RCRHelpDesk@mih.gov', 'PMB policies and guidelines:', 'ttp://ctep.cancer.gov/branches/pmb/agent management.htm', 'PMB Online Agent Order Processing (OAOP) application:', 'https://ctepcore.nci.nih.gov/OAOP', 'CTEP Identity and Access Management (IAM) account: https://ctepcore.nci.nih.gov/iam/', 'CTEP IAM account help: ctepreghelp@ctep.nci.nih.gov', 'IB Coordinator: IBCoordinator@mail.nih.gov', 'PMB email: PMBAfterHours@mail.nih.gov', 'PMB phone and hours of service: (240) 276-6575 Monday through Friday between 8:30 am and', '4:30 pm (ET)', '15.1.2 Incompatibilities', 'Drug-drug interaction studies have not been conducted with SGI-110 or decitabine. In vitro', 'studies in human hepatocytes suggest that SGI-110 is unlikely to inhibit or induct cytochrome', 'p450 enzymes. Thus p450-mediated drug-drug interactions are not anticipated for SGI-110.']"
56,page_57,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '57', 'Version Date: 07/22/2019', '16 APPENDICES', '16.1 APPENDIX I-PERFORMANCE STATUS CRITERIA', 'Patient C3D Study ID:', ""Patient's Age:"", 'ECOG Performance Status Scale', 'Karnofsky Performance Scale', 'Grade', 'Descriptions', 'Percent', 'Description', 'Normal, no complaints, no evidence of', 'Normal activity. Fully active,', '100', 'disease.', '0', 'able to carry on all pre-disease', 'performance without restriction.', 'Able to carry on normal activity; minor', '90', 'signs or symptoms of disease.', 'Symptoms, but ambulatory.', 'Normal activity with effort; some signs', 'Restricted in physically strenuous', '80', 'or symptoms of disease.', 'activity, but ambulatory and able', '1', 'to carry out work of a light or', 'sedentary nature (e.g., light', 'Cares for self, unable to carry on', '70', 'housework, office work).', 'normal activity or to do active work.', 'In bed <50% of the time.', 'Requires occasional assistance, but is', '60', 'Ambulatory and capable of all', 'able to care for most of his/her needs.', 'self-care, but unable to carry out', '2', 'Requires considerable assistance and', 'any work activities. Up and', 'about more than 50% of waking', '50', 'frequent medical care.', 'hours.', 'In bed >50% of the time.', 'Disabled, requires special care and', '40', 'Capable of only limited self-care,', 'assistance.', '3', 'confined to bed or chair more', 'Severely disabled, hospitalization', 'than 50% of waking hours.', '30', 'indicated. Death not imminent.', '100% bedridden. Completely', 'Very sick, hospitalization indicated.', '20', 'disabled. Cannot carry on any', 'Death not imminent.', '4', 'self-care. Totally confined to bed', 'Moribund, fatal processes progressing', 'or chair.', '10', 'rapidly.', '5', 'Dead.', '0', 'Dead.', 'PERFORMANCE STATUS:', 'ECOG Score:', 'OR', 'Karnofsky Score:']"
57,page_58,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '58', 'Version Date: 07/22/2019', '16.2 APPENDIX II: PERFORMANCE STATUS SCALES/SCORES IN PATIENTS <16 YEARS OFAGE', 'Patient C3D Study ID:', ""Patient's Age:"", 'PERFORMANCE STATUS CRITERIA', 'Karnofsky and Lansky performance scores are intended to be multiples of 10', 'Karnofsky (> 16 years of age)', 'Lansky (16 years of age)', 'Score', 'Description', 'Score', 'Description', '100', 'Normal, no complaints, no evidence', '100', 'Fully active, normal.', 'of disease', '90', 'Able to carry on normal activity,', '90', 'Minor restrictions in physically strenuous', 'minor signs or symptoms of disease.', 'activity.', 'Normal activity with effort; some', '80', '80', 'signs or symptoms of disease.', 'Active, but tires more quickly', '70', 'Cares for self, unable to carry on', '70', 'Both greater restriction of and less time', 'normal activity or do active work.', 'spent in play activity.', '60', 'Required occasional assistance, but is', '60', 'Up and around, but minimal active play;', 'able to care for most of his/her needs.', 'keeps busy with quieter activities.', '50', 'Requires considerable assistance and', '50', 'Gets dressed, but lies around much of the', 'frequent medical care.', 'day; no active play, able to participate in', 'all quiet play and activities.', '40', 'Disabled, requires specia care and', '40', 'Mostly in bed; participates in quiet', 'assistance.', 'activities.', '30', 'Severely disabled, hospitalization', '30', 'In bed; needs assistance even for quiet', 'indicated. Death not imminent.', 'play.', '20', 'Very sick, hospitalization indicated.', '20', 'Often sleeping; play entirely limited to', 'Death not imminent.', 'very passive activities.', '10', 'Moribund, fatal processes progressing', '10', 'No play; does not get out of bed.', 'rapidly.', 'PERFORMANCE STATUS:', 'Karnofsky Score:', 'OR', 'Lansky Score:']"
58,page_59,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '59', 'Version Date: 07/22/2019', '16.3 APPENDIX III: QUALITY OF LIFE TOOLS', '16.3.1 Pediatric PROMIS Instruments English (6)', 'PROMIST Pediatric Item Bank v.1.0 - Physical Function - Mobility Short Form 8a', 'Pediatric Physical Function - Mobility - Short Form', 'Please respond to each item by marking one box per row.', 'In the past 7 days', 'With no', 'With a little', 'With some', 'With a lot of', 'trouble', 'trouble', 'trouble', 'trouble', 'Not able to do', 'I could do sports and', 'exercise that other kids my', 'age could do.', '4', '3', '2', '1', '0', 'I could get up from the', 'floor.', '4', '3', '2', '1', '0', 'I could keep up when I', 'played with other kids.', '4', '3', '2', '1', '0', 'I could move my legs.', '4', '3', '2', '1', '0', 'I could stand up by myself.', '4', '3', '2', '1', '0', 'I could stand up on my', 'tiptoes.', '4', '3', '2', '1', '0', 'I could walk up stairs', 'without holding on to', 'anything.', '4', '3', '2', '1', '0', 'I have been physically able', 'to do the activities I enjoy', 'most.', '4', '3', '2', '1', '0', 'c 2009-2012 PROMISTM Health Organization and PROMIS Cooperative Group']"
59,page_60,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '60', 'Version Date: 07/22/2019', 'PROMIS Pediatric Item Bank v2.0 - Anxiety - Short Form 8a', 'Pediatric Anxiety - Short Form 8a', 'Please respond to each question or statement by marking one box per row.', 'In the past 7 days.', 'Almost', 'Almost', 'Never', 'Never', 'Sometimes', 'Often', 'Always', '2220R2r', 'I felt like something awful might happen..', '1', '2', '3', '4', '5', '713R1r', 'I felt nervous', '1', '2', '3', '4', '5', '227bR1r', 'I felt scared', '1', '2', '3', '4', '5', '5044R1r', 'I felt worried', '1', '2', '3', '4', '5', '3459bR1r', 'I worried when I was at home', '1', '2', '3', '4', '5', '2230R1r', 'I got scared really easy', '1', '2', '3', '4', '5', '231R1r', 'I worried about what could happen to me.', '1', '2', '3', '4', '5', '3150bR2r', 'I worried when I went to bed at night', '1', '2', '3', '4', '5', 'Last Update: 27 July 2016', '© 2010-2016 PROMIS Health Organization and PROMIS Cooperative Group', 'Page of 1']"
60,page_61,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '61', 'Version Date: 07/22/2019', 'PROMIS Pediatric Item Bank v2.0 - Depressive Symptoms - Short Form 8a', 'Pediatric Depressive Symptoms - Short Form 8a', 'Please respond to each question or statement by marking one box per row.', 'In the past 7 days.', 'Almost', 'Almost', 'Never', 'Never', 'Sometimes', 'Often', 'Always', '488R1r', 'I could not stop feeling sad', '1', '2', '3', '4', '5', '461R1r', 'I felt alone', '1', '2', '3', '4', '5', '5041R1r', 'I felt everything in my life went wrong', '1', '2', '3', '4', '5', '5035R1r', ""I felt like I couldn't do anything right"", '1', '2', '3', '4', '5', '711R1r', 'I felt lonely', '1', '2', '3', '4', '5', '228R1r', 'I felt sad', '1', '2', '3', '4', '5', '712R1r', 'I felt unhappy', '1', '2', '3', '4', '5', '3952aR2r', 'It was hard for me to have fun', '1', '2', '3', '4', '5', 'Last Updated: 28 July 2016', '© 2010-2016 PROMIS Health Organization and PROMIS Cooperative Group', 'Page of 1']"
61,page_62,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '62', 'Version Date: 07/22/2019', 'PROMISTM Pediatric Item Bank v.1.0 - Fatigue Short Form 10a', 'Pediatric Fatigue - Short Form', 'Please respond to each item by marking one box per row.', 'In the past 7 days', 'Never', 'Almost Never', 'Sometimes', 'Often', 'Almost Always', 'Being tired made it hard for me to play or', ""go out with my friends as much as I'd"", 'like.', '0', '1', '2', '3', '4', 'I felt weak.', '0', '1', '2', '3', '4', 'I got tired easily.', '0', '1', '2', '3', '4', 'Being tired made it hard for me to keep', 'up with my schoolwork.', '0', '1', '2', '3', '4', 'I had trouble finishing things because I', 'was too tired.', '0', '1', '2', '3', '4', 'I had trouble starting things because I', 'was too tired.', '0', '1', '2', '3', '4', 'I was so tired it was hard for me to pay', 'attention.', '0', '1', '2', '3', '4', 'I was too tired to do sports or exercise.', '0', '1', '2', '3', '4', 'I was too tired to do things outside.', '0', '1', '2', '3', '4', 'I was too tired to enjoy the things I like', 'to do.', '0', '1', '2', '3', '4', '© 2009-2012 PROMISTM Health Organization and PROMIS Cooperative Group']"
62,page_63,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '63', 'Version Date: 07/22/2019', 'PROMISTM Pediatric Item Bank v.1.0 - Pain Interference - Short Form 8a', 'Pediatric Pain Interference - Short Form', 'Please respond to each item by marking one box per row.', 'In the past 7 days', 'Never', 'Almost Never', 'Sometimes', 'Often', 'Almost Always', 'I had trouble sleeping when I', 'had pain.', '0', '1', '2', '3', '4', 'I felt angry when I had pain.', '0', '1', '2', '3', '4', 'I had trouble doing schoolwork', 'when I had pain.', '0', '1', '2', '3', '4', 'It was hard for me to pay', 'attention when I had pain.', '0', '1', '2', '3', '4', 'It was hard for me to run when', 'I had pain.', '0', '1', '2', '3', '4', 'It was hard for me to walk one', 'block when I had pain.', '0', '1', '2', '3', '4', 'It was hard to have fun when I', 'had pain.', '0', '1', '2', '3', '4', 'It was hard to stay standing', 'when I had pain.', '0', '1', '2', '3', '4', 'C 2009-2012 PROMISTM Health Organization and PROMIS Cooperative Group']"
63,page_64,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '64', 'Version Date: 07/22/2019', 'PROMISTM Pediatric Item Bank V. 1.0 - Peer Relationships - Short Form 8a', 'Pediatric Peer Relationships - Short Form', 'Please respond to each item by marking one box per row.', 'In the past 7 days', 'Never', 'Almost Never', 'Sometimes', 'Often', 'Almost Always', 'I felt accepted by other kids my', 'age.', '0', '1', '2', '3', '4', 'I was able to count on my', 'friends.', '0', '1', '2', '3', '4', 'I was able to talk about', 'everything with my friends.', '0', '1', '2', '3', '4', 'I was good at making friends.', '0', '1', '2', '3', '4', 'My friends and I helped each', 'other out.', '0', '1', '2', '3', '4', 'Other kids wanted to be my', 'friend.', '0', '1', '2', '3', '4', 'Other kids wanted to be with', 'me.', '0', '1', '2', '3', '4', 'Other kids wanted to talk to', 'me.', '0', '1', '2', '3', '4', '© 2009-2012 PROMISTM Health Organization and PROMIS Cooperative Group']"
64,page_65,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '65', 'Version Date: 07/22/2019', '16.3.2 Pediatric PROMIS Instruments Spanish (6)', 'PROMIS Pediatric v.1.1 - Depressive Symptoms - Short Form 8b', 'Síntomas de depresión en pediatría - Cuestionario abreviado 8b', 'Responde a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Nunca', 'Casi nunca', 'Aveces', 'A menudo', 'Casi siempre', 'No pude dejar de', 'sentirme triste.', '0', '1', '2', '3', '4', '4SIRT', 'Senti que estaba solo/a.', 'o', '1', '2', '3', '4', 'Senti que todo me salía', '5041R1', 'mal en la vida.', '0', '1', '2', '3', '4', '5035R1', 'Senti que no podía hacer', 'nada bien.', 'o', '1', '2', '3', '4', '711R1', 'Me senti solo/a.', 'o', '1', '2', '3', '4', '226R1', 'Me senti triste.', '0', '1', '2', '3', '4', '71281', 'Me senti descontento/a.', 'o', '1', '2', '3', '4', 'Me resultó difícil', 'divertirme.', 'o', '1', '2', '3', '4', 'Spanish (Universal)', '27 January 2014', 'e 2009-2013 PROMIS Health Organization and PROMIS Cooperative Group']"
65,page_66,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '66', 'Version Date: 07/22/2019', 'PROMISTM Pediatric Item Bank v. 1.0 - Fatigue Short Form 10a', 'Agotamiento en niños - Cuestionario abreviado 10a', 'Responde a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Nunca', 'Casi nunca', 'A veces', 'Amenudo', 'Casi siempre', 'El', 'cansancio hizo que fuera difícil', 'para mi estar al día con las tareas', 'escolares.', '0', '1', '2', '3', '4', 'Como estaba cansado/a, me resultó', 'CH3R1', 'difícil jugar o salir con mis amigos/as', 'tanto como me habría gustado.', '0', '1', '2', '3', '4', '413R1', 'Senti debilidad.', '0', '1', '2', '3', '4', '267681', 'Me cansé fácilmente.', '0', '1', '2', '3', '4', 'Tuve dificultad para terminar las', '02181', 'cosas porque estaba demasiado', 'cansado/a.', '0', '1', '2', '3', '4', 'Tuve dificultad para comenzar las', '4220811', 'cosas porque estaba demasiado', 'cansado/a.', '0', '1', '2', '3', '4', 'Estuve tan cansado/a que me fue', '421083', 'difícil prestar atención.', '0', '1', '2', '3', '4', 'Estuve demasiado cansado/a para', 'practicar deportes o hacer ejercicio.', '0', '1', '2', '3', '4', 'Estuve demasiado cansado/a para', 'hacer actividades (a)fuera.', '0', '1', '2', '3', '4', 'Estuve demasiado cansado/a para', '419081', 'disfrutar de las cosas que me gusta', 'hacer.', '0', '1', '2', '3', '4', 'Spanish (Universal)', '26 February 2013', 'o 2009-2012 PROMIST Health Organization and PROMIS Cooperative Group']"
66,page_67,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '67', 'Version Date: 07/22/2019', 'PROMISTM Pediatric Item Bank v.1.0 - Physical Function - Mobility - Short Form 8a', 'Capacidad de funcionamiento físico en niños - Movilidad - Cuestionario abreviado 8a', 'Responde a cada enunciado marcando una casilla por línea.', 'En los últimos 7 dias', 'Con poca', 'Con alguna', 'Con mucha', 'No pude', 'Sin dificultad', 'dificultad', 'dificultad', 'dificultad', 'hacerlo', 'Pude practicar los mismos', 'deportes y ejercicios que', '236R1', 'hacían otros niños/as de mi', 'edad.', '4', '3', '2', '1', '0', 'Pude levantarme del piso', '4124R1', '(suelo).', '4', '3', '2', '1', '0', 'Pude mantener el mismo', '236R1', 'ritmo cuando jugaba con', 'otros niños/as.', '4', '3', '2', '1', '0', 'Pude mover las piernas.', '4', '3', '2', '1', '0', 'Pude ponerme de pie sin', '2646R1', 'ayuda.', '4', '3', '2', '1', '0', 'Pude ponerme de puntillas', '4155R1', '(sobre las puntas de los', 'pies).', '4', '3', '2', '1', '0', 'Pude subir escaleras sin', '2707122', 'agarrarme a nada.', '4', '3', '2', '1', '0', 'He podido hacer', 'físicamente las actividades', 'que más me gustan.', '4', '3', '2', '1', '0', 'Spanish (Universal)', '26 February 2013', 'e 2009-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'TM']"
67,page_68,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '68', 'Version Date: 07/22/2019', 'PROMISTM Pediatric Item Bank v. 1.0 - Pain Interference - Short Form 8a', 'Efectos del dolor en niños - Cuestionario abreviado 8a', 'Responde a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Nunca', 'Casi nunca', 'A veces', 'A menudo', 'Casi siempre', 'Me senti enojado/a', '16006R1', 'cuando tuve dolor.', '0', '1', '2', '3', '4', 'Cuando tuve dolor, tuve', '2005R1', 'problemas para hacer', 'las tareas escolares.', '0', '1', '2', '3', '4', 'Tuve problemas para', '3793R1', 'dormir cuando senti', 'dolor.', '0', '1', '2', '3', '4', 'Cuando tuve dolor, me', '9004', 'fue difícil prestar', 'atención.', '0', '1', '2', '3', '4', 'Cuando tuve dolor, me', '2045R1', 'fue difícil correr.', 'o', '1', '2', '3', '4', 'Cuando tuve dolor, me', '2049R1', 'fue difícil caminar una', 'manzana (cuadra).', 'o', '1', '2', '3', '4', 'Cuando tuve dolor, fue', '1703R1', 'difícil para mi divertirme.', '0', '1', '2', '3', '4', 'Cuando tuve dolor, fue', '2160R1', 'difícil para mi quedarme', 'de pie.', '0', '1', '2', '3', '4', 'Spanish (Universal)', '26 February 2013', 'e 2009-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'TM']"
68,page_69,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '69', 'Version Date: 07/22/2019', 'PROMIS Pediatric Item Bank v. 1.0 - Peer Relationships - Short Form 8a', 'Relaciones entre iguales en niños - Cuestionario abreviado 8a', 'Responde a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Nunca', 'Casi nunca', 'A veces', 'A menudo', 'Casi siempre', 'Me senti aceptado/a por', '5018R1', 'los otros niños/as de mi', 'edad.', '0', '1', '2', '3', '4', 'Pude contar con mis', '5056R1', 'amigos/as.', '0', '1', '2', '3', '4', 'Pude hablar de todo con', '5056R1', 'mis amigos/as.', '0', '1', '2', '3', '4', 'Me fue fácil hacer', '1147R1', 'amigos/as.', '0', '1', '2', '3', '4', 'Mis amigos/as y yo nos', '5066R1', 'ayudamos.', '0', '1', '2', '3', '4', 'Otros niños/as quisieron', '233R2', 'ser mis amigos/as.', '0', '1', '2', '3', '4', 'Otros niños/as quisieron', '210R1', 'estar conmigo.', '0', '1', '2', '3', '4', 'Otros niños/as quisieron', '9020R1', 'hablar conmigo.', '0', '1', '2', '3', '4', 'Spanish (Universal)', '26 February 2013', '- 2009-2012 PROMIS Health Organization and PROMIS Cooperative Group']"
69,page_70,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '70', 'Version Date: 07/22/2019', 'PROMIS Pediatric v.1.1 - Anxiety - Short Form 8b', 'Ansiedad en pediatría - Cuestionario abreviado 8b', 'Responde a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Nunca', 'Casi nunca', 'Aveces', 'Amenudo', 'Casi siempre', 'Senti que podría pasar', '2220R2', 'algo terrible.', '0', '1', '2', '3', '4', '713R1', 'Me senti nervioso/a.', '0', '1', '2', '3', '4', '2276R1', 'Senti miedo.', '0', '1', '2', '3', '4', '5044R1', 'Me senti preocupado/a.', '0', '1', '2', '3', '4', 'Me preocupé cuando', '34506R1', 'estaba en casa.', '0', '1', '2', '3', '4', 'Me asusté con mucha', '2230R1', 'facilidad.', '0', '1', '2', '3', '4', 'Me preocupó lo que', '23181', 'pudiera pasarme.', '0', '1', '2', '3', '4', 'Me preocupé al', '31506/22', 'acostarme por las', 'noches.', '0', '1', '2', '3', '4', 'Spanish (Universal)', '27 January 2014', '- 2009-2013 PROMIS Health Organization and PROMIS Cooperative Group']"
70,page_71,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '71', 'Version Date: 07/22/2019', '16.3.3 Parallel Parent Proxy PROMIS Instruments English (6)', 'PROMIS Parent Proxy Item Bank v1.0 - Physical Function Mobility 8', 'Physical Function Mobility - Short Form 8', 'Please respond to each question or statement by marking one box per row.', 'With a', 'In the past 7 days', 'With no', 'little', 'With some', 'With a lot', 'Not able to', 'trouble', 'trouble', 'trouble', 'of trouble', 'do', 'My child could do sports and exercise that', 'Pfimobil3', 'other kids his/her age could do', '4', '3', '2', '1', '0', 'Pf3mobil9', 'My child could get up from the floor', '4', '3', '2', '1', '0', 'My child could keep up when he/she', 'Pf4mobil4', 'played with other kids', '4', '3', '2', '1', '0', 'Pf3mobil8', 'My child could move his/her legs', '4', '3', '2', '1', '0', 'Pf3mobil3', 'My child could stand up without help', '4', '3', '2', '1', '0', 'My child could stand up on his/her', 'Pf2mobil7', 'tiptoes', '4', '3', '2', '1', '0', 'My child could walk up stairs without', 'Pf2mobil4', 'holding on to anything', '4', '3', '2', '1', '0', 'My child has been physically able to do', 'Pfimobili', 'the activities he/she enjoys most', '4', '3', '2', '1', '0', 'C', '2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page of 1']"
71,page_72,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '72', 'Version Date: 07/22/2019', 'PROMIS Parent Proxy Item Bank v1.0 - Anxiety 8', 'Anxiety - Short Form 8', 'Please respond to each question or statement by marking one box per row.', 'Almost', 'Almost', 'In the past 7 days', 'Never', 'Never', 'Sometimes', 'Often', 'Always', 'Pf1anxiety8', 'My child felt nervous', '0', '1', '2', '3', '4', 'Pf2anxiety2', 'My child felt scared', '0', '1', '2', '3', '4', 'P12anxiety', 'My child felt worried', '0', '1', '2', '3', '4', 'My child felt like something awful might', 'Pf2anxiety1', 'happen', '0', '1', '2', '3', '4', 'Pf2 anxiety6', 'My child thought about scary things', '0', '1', '2', '3', '4', 'My child was afraid that he/she would', 'Pf1anxiety7', 'make mistakes', '0', '1', '2', '3', '4', 'My child worried about what could', 'Pf1anxiety3', 'happen to him/her', '0', '1', '2', '3', '4', 'My child worried when he/she went to', 'Pf2 anxiety4', 'bed at night', '0', '1', '2', '3', '4', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
72,page_73,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '73', 'Version Date: 07/22/2019', 'PROMIS Parent Proxy Item Bank v1.0 - Depressive Symptoms 6', 'Depressive Symptoms - Short Form 6', 'Please respond to each question or statement by marking one box per row.', 'Almost', 'Almost', 'In the past 7 days', 'Never', 'Never', 'Sometimes', 'Often', 'Always', 'Pf2depr7', 'My child could not stop feeling sad', '0', '1', '2', '3', '4', 'My child felt everything in his/her life', 'Pfidepr7', 'went wrong', '0', '1', '2', '3', '4', ""My child felt like he/she couldn't do"", 'Pfidepr5', 'anything right', '0', '1', '2', '3', '4', 'Pf2depr 10', 'My child felt lonely', '0', '1', '2', '3', '4', 'Pf2depr3', 'My child felt sad', '0', '1', '2', '3', '4', 'Pf2depr5', 'My child thought that his/her life was bad', '0', '1', '2', '3', '4', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
73,page_74,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '74', 'Version Date: 07/22/2019', 'PROMIS Parent Proxy Item Bank v1.0 - Fatigue 10', 'Fatigue - Short Form 10', 'Please respond to each question or statement by marking one box per row.', 'Almost', 'Almost', 'In the past 7 days', 'Never', 'Never', 'Sometimes', 'Often', 'Always', 'Being tired made it hard for my child to', 'Pf4fatigue12', 'play or go out with friends as much as', '0', '1', '2', '3', '4', 'he/she would like', 'Pf4fatigue8', 'My child felt weak', '0', '1', '2', '3', '4', 'Pf4fatigue3', 'My child got tired easily', '0', '1', '2', '3', '4', 'Being tired made it hard for my child to', 'Pf2fatigue8', 'keep up with schoolwork', '0', '1', '2', '3', '4', 'My child had trouble finishing things', 'Pf2fatigue4', 'because he/she was too tired', '0', '1', '2', '3', '4', 'My child had trouble starting things', 'Pf3fatigue7', 'because he/she was too tired', '0', '1', '2', '3', '4', 'My child was so tired it was hard for', 'Pf3fatigue12', 'him/her to pay attention', '0', '1', '2', '3', '4', 'My child was too tired to do sports or', 'Pf3fatigue8', 'exercise', '0', '1', '2', '3', '4', 'My child was too tired to do things', 'Pf3fatigue4', 'outside', '0', '1', '2', '3', '4', 'My child was too tired to enjoy the things', 'Pf4fatigue4', 'he/she likes to do', '0', '1', '2', '3', '4', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
74,page_75,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '75', 'Version Date: 07/22/2019', 'PROMIS Parent Proxy Item Bank V1.0-Pain - Interference 8', 'Pain Interference - Short Form 8', 'Please respond to each question or statement by marking one box per row.', 'Almost', 'Almost', 'In the past 7 days', 'Never', 'Never', 'Sometimes', 'Often', 'Always', 'My child had trouble sleeping when', 'Pf2pain5', 'he/she had pain', '0', '1', '2', '3', '4', 'Pf3pain7', 'My child felt angry when he/she had pain', '0', '1', '2', '3', '4', 'My child had trouble doing schoolwork', 'Pf2pain2', 'when he/she had pain', '0', '1', '2', '3', '4', 'It was hard for my child to pay attention', 'Pf3pain2', 'when he/she had pain', '0', '1', '2', '3', '4', 'It was hard for my child to run when', 'Pf2pain4', 'he/she had pain', '0', '1', '2', '3', '4', 'It was hard for my child to walk one block', 'Pf1pain4', 'when he/she had pain', '0', '1', '2', '3', '4', 'It was hard for my child to have fun when', 'Pf3pain4', 'he/she had pain', '0', '1', '2', '3', '4', 'It was hard for my child to stay standing', 'Pf4paint', 'when he/she had pain', '0', '1', '2', '3', '4', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
75,page_76,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '76', 'Version Date: 07/22/2019', 'PROMIS Parent Proxy Item Bank v1.0 - Peer Relationships 7', 'Peer Relationships - Short Form 7', 'Please respond to each question or statement by marking one box per row.', 'Almost', 'Almost', 'In the past 7 days', 'Never', 'Never', 'Sometimes', 'Often', 'Always', 'My child felt accepted by other kids', 'Pf3socabil9', 'his/her age', '0', '1', '2', '3', '4', 'My child was able to count on his/her', 'Pf4socabil12', 'friends', '0', '1', '2', '3', '4', 'Pf3soc: abil4', 'My child was good at making friends', '0', '1', '2', '3', '4', 'My child and his/her friends helped each', 'Pf2socrole4', 'other out', '0', '1', '2', '3', '4', 'Pfisocabil2', ""Other kids wanted to be my child's friend."", '0', '1', '2', '3', '4', 'Pf3socrole4', 'Other kids wanted to be with my child', '0', '1', '2', '3', '4', 'Pf2socabil9', 'Other kids wanted to talk to my child', '0', '1', '2', '3', '4', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
76,page_77,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '77', 'Version Date: 07/22/2019', '16.3.4 Adult Patient PROMIS Instruments English (6)', 'PROMIS Item Bank v1.0-Physical Function - Short Form 10a', 'Physical Function - Short Form 10a', 'Please respond to each item by marking one box per row.', 'Not at all', 'Very little', 'Somewhat', 'Quite a lot', 'Cannot do', 'Does your health now limit you in doing vigorous', 'PFA01', 'activities, such as running, lifting heavy objects,', '5', '4', '3', '2', '1', 'participating in strenuous sports?', 'Does your health now limit you in walking more', 'PFC36', 'than a mile?', '5', '4', '3', '2', '1', 'Does your health now limit you in climbing one', 'PFC37', 'flight of stairs?', '5', '4', '3', '2', '1', 'Does your health now limit you in lifting or', 'PFA05', 'carrying groceries?', '5', '4', '3', '2', '1', 'Does your health now limit you in bending,', 'PFA03', 'kneeling, or stooping?', '5', '4', '3', '2', '1', 'Without', 'With a', 'With', 'With', 'any', 'little', 'some', 'much', 'Unable to', 'difficulty', 'difficulty', 'difficulty', 'difficulty', 'do', 'PFA11', 'Are you able to do chores such as vacuming or', '5', '4', '3', '2', '1', 'yard work?', 'PFA16', 'Are you able to dress yourself, including tying', '5', '4', '3', '2', '1', 'shoelaces and doing buttons?', 'PFB26', 'Are you able to shampoo your hair?', '5', '4', '3', '2', '1', 'PFA55', 'Are you able to wash and dry your body?', '5', '4', '3', '2', '1', 'PFC45', 'Are you able to get on and off the toilet?', '5', '4', '3', '2', '1', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page of 1']"
77,page_78,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '78', 'Version Date: 07/22/2019', 'PROMIS Item Bank V. 1.0 - Emotional Distress - Anxiety- Short Form 7a', 'Emotional Distress - Anxiety - Short Form 7a', 'Please respond to each item by marking one box per row.', 'In the past 7 days...', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'EDANX01', 'I felt fearful', '1', '2', '3', '4', '5', 'EDANX05', 'I felt anxious', '1', '2', '3', '4', '5', 'EDANX30', 'I felt worried', '1', '2', '3', '4', '5', 'I found it hard to focus on anything', 'EDANX40', 'other than my anxiety', '1', '2', '3', '4', '5', 'EDANX46', 'I felt nervous', '1', '2', '3', '4', '5', 'EDANX53', 'I felt uneasy', '1', '2', '3', '4', '5', 'EDANX54', 'I felt tense', '1', '2', '3', '4', '5', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group']"
78,page_79,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '79', 'Version Date: 07/22/2019', 'PROMIS Item Bank v. 1.0 - Emotional Distress - Depression - Short Form 8b', 'Emotional Distress - Depression - Short Form 8b', 'Please respond to each item by marking one box per row.', 'In the past 7 days.', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'EDDEP04', 'I felt worthless', '1', '2', '3', '4', '5', 'EDDEP05', 'I felt that I had nothing to look forward', 'to', '1', '2', '3', '4', '5', 'EDDEP06', 'I felt helpless', '1', '2', '3', '4', '5', 'EDDEP17', 'I felt sad', '1', '2', '3', '4', '5', 'EDDEP22', 'I felt like a failure', '1', '2', '3', '4', '5', 'EDDEP29', 'I felt depressed', '1', '2', '3', '4', '5', 'EDDEP36', 'I felt unhappy', '1', '2', '3', '4', '5', 'EDDEP41', 'I felt hopeless', '1', '2', '3', '4', '5', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group']"
79,page_80,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '80', 'Version Date: 07/22/2019', 'PROMIS Item Bank v. 1.0 - Fatigue Short Form 7a', 'Fatigue - Short Form 7a', 'Please respond to each question by marking one box per row.', 'In the past 7 days', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'FATEXP20', 'How often did you feel tired?', '1', '2', '3', '4', '5', 'How often did you experience extreme', 'FATEXP5', 'exhaustion?', '1', '2', '3', '4', '5', 'How often did you run out of', 'FATEXP18', '1', '2', '3', '4', '5', 'energy?', 'How often did your fatigue limit you at', 'ATIMP33', '1', '2', '3', '4', '5', 'work (include work at home)?', 'How often were you too tired to think', 'FATIMP30', '1', '2', '3', '4', '5', 'clearly?', 'How often were you too tired to take a', 'FATIMP21', 'bath or shower?', '1', '2', '3', '4', '5', 'How often did you have enough energy', 'FATIMP40', '5', '4', '3', '2', '1', 'to exercise strenuously?', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group']"
80,page_81,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '81', 'Version Date: 07/22/2019', 'PROMIS Item Bank v1.0 - Pain Interference - Short Form 6b', 'Pain Interference - Short Form 6b', 'Please respond to each item by marking one box per row.', 'In the past 7 days.', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', 'PAININ3', 'How much did pain interfere with your', 'enjoyment of life?', '1', '2', '3', '4', '5', 'PAININ8', 'How much did pain interfere with your ability', 'to concentrate?', '1', '2', '3', '4', '5', 'PAININ9', 'How much did pain interfere with your day to', 'day activities?', '1', '2', '3', '4', '5', 'How much did pain interfere with your', 'PAININ10', 'enjoyment of recreational activities?', '1', '2', '3', '4', '5', 'How much did pain interfere with doing your', 'PAININ14', 'tasks away from home (e.g., getting groceries,', '1', '2', '3', '4', '5', 'running errands)?', 'In the past 7 days.', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'How often did pain keep you from socializing', 'PAININ26', 'with others?', '1', '2', '3', '4', '5', 'C 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page of 1']"
81,page_82,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '82', 'Version Date: 07/22/2019', 'PROMIS v.1.0/1.1 Global', 'Global Health Scale', 'Please respond to each item by marking one box per row.', 'Very', 'Excellent', 'good', 'Good', 'Fair', 'Poor', 'Global01', 'In general, would you say your health is:', '5', '4', '3', '2', '1', 'In general, would you say your quality of', 'Global02', 'life is:', '5', '4', '3', '2', '1', 'In general, how would you rate your physical', 'Global03', 'health?', '5', '4', '3', '2', '1', 'In general, how would you rate your mental', 'Global04', 'health, including your mood and your ability to', '5', '4', '3', '2', '1', 'think?', 'In general, how would you rate your satisfaction', 'Global05', 'with your social activities and relationships?', '5', '4', '3', '2', '1', 'In general, please rate how well you carry out', 'your usual social activities and roles. (This', 'includes activities at home, at work and in your', 'Global09', '5', '4', '3', '2', '1', 'community, and responsibilities as a parent,', 'child, spouse, employee, friend, etc.)', 'Completely', 'Mostly', 'Moderately', 'A little', 'Not at all', 'To what extent are you able to carry out your', 'everyday physical activities such as walking,', 'Global06', 'climbing stairs, carrying groceries, or moving a', '5', '4', '3', '2', '1', 'chair?', '© 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 2']"
82,page_83,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '83', 'Version Date: 07/22/2019', 'PROMIS V .1.0/1.1 Global', 'In the past 7 days', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'How often have you been bothered by emotional', 'Global10', 'problems such as feeling anxious, depressed or', '1', '2', '3', '4', '5', 'irritable?', 'Very', 'None', 'Mild', 'Moderate', 'Severe', 'severe', 'Global08', 'How would you rate your fatigue on average?', '1', '2', '3', '4', '5', 'Global07', 'How would you rate your', 'pain on average?', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'No', 'Worst', 'pain', 'imaginable', 'pain', 'C. 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 2 of 2']"
83,page_84,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '84', 'Version Date: 07/22/2019', '16.3.5 Adult Patient PROMIS Instruments Spanish (6)', 'PROMIS Item Bank V. 1.2 - Physical Function - Short Form 10a', 'Capacidad de funcionamiento físico - Cuestionario abreviado 10a', 'Responda a cada pregunta marcando una casilla por línea.', 'No puedo', 'Nada', 'Poco', 'Algo', 'Mucho', 'hacerlo', '¿Limita su salud en este momento su capacidad', 'PFA1', 'para realizar actividades vigorosas, como correr,', '5', '4', '3', '2', '1', 'levantar objetos pesados o participar en deportes', 'enérgicos?', '¿Limita su salud en este momento su capacidad', 'PFC36r1', 'para caminar más de una milla (1.6 km)?', '5', '4', '3', '2', '1', 'PFC37', '¿Limita su salud en este momento su capacidad', 'para subir un piso de escaleras?', '5', '4', '3', '2', '1', 'Limita su salud en este momento su capacidad', 'PFAS', 'para levantar o llevar las bolsas del', '5', '4', '3', '2', '1', 'supermercado?', '¿Limita su salud en este momento su capacidad', 'PFA3', 'para inclinarse, arrodillarse o agacharse?', '5', '4', '3', '2', '1', 'Con', 'Con', 'Sin', 'Con poca', 'alguna', 'mucha', 'No puedo', 'dificultad', 'dificultad', 'dificultad', 'dificultad', 'hacerlo', 'PFA11', '¿Puede realizar tareas, como pasar la aspiradora', '5', '4', '3', '2', '1', 'o trabajar en el jardin?', 'PFA16r1', '¿Puede vestirse sin ayuda, incluso amarrarse los', '5', '4', '3', '2', '1', 'zapatos y abotonarse la ropa?', 'PFB26', '¿Puede lavarse el cabello con champú?', '5', '4', '3', '2', '1', 'PFASS', 'Puede lavarse y secarse el cuerpo?', '5', '4', '3', '2', '1', 'PFC45r1', 'Puede sentarse y levantarse del inodoro', '(excusado)?', '5', '4', '3', '2', '1', 'Spanish (Universal)', '21 January 2014', 'o 2008-2013 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
84,page_85,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '85', 'Version Date: 07/22/2019', 'PROMIS Item Bankv. 1.0 - Emotional Distress - Anxiety - Short Form 7a', 'Trastorno emocional - Ansiedad - Cuestionario abreviado 7a', 'Responda a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Algunas', 'Nunca', 'Raravez', 'veces', 'A menudo', 'Sie mpre', 'Senti miedo', 'EDANKO', '1', '2', '3', '4', '5', 'EDANKOS', 'Senti ansiedad', '1', '2', '3', '4', '5', 'EDANICIO', 'Me senti preocupado/a', '1', '2', '3', '4', '5', 'Tuve dificultad para concentrarme en', 'otra cosa que no fuera mi ansiedad', '1', '2', '3', '4', '5', 'EDANKAS', 'Me senti nervioso/a', '1', '2', '3', '4', '5', 'EDANKOSS', 'Me senti intranquilo/a', '1', '2', '3', '4', '5', 'EDANKOS', 'Me senti tenso/a', '1', '2', '3', '4', '5', 'Spanish (Universal)', '24 April 2012', 'o 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
85,page_86,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '86', 'Version Date: 07/22/2019', 'PROMIS Item Bank V. 1.0 - Emotional Distress - Depression - Short Form 8b', 'Trastorno emocional - Depresión - Cuestionario abreviado 8b', 'Responda a cada enunciado marcando una casilla por línea.', 'En los últimos 7 días', 'Algunas', 'Nunca', 'Rara vez', 'veces', 'A menudo', 'Siempre', 'ECDEPO4', 'Senti que no valía nada', '1', '2', '3', '4', '5', 'ECDEPOS', 'Senti que nada me ilusionaba', '1', '2', '3', '4', '5', 'Me senti indefenso/a (que no podía', 'ECDEPOS', 'hacer nada para ayudarme)', '1', '2', '3', '4', '5', 'ECDEP17', 'Me senti triste', '1', '2', '3', '4', '5', 'ECDEP22', 'Me senti fracasado/a', '1', '2', '3', '4', '5', 'ECDEP29', 'Me senti deprimido/a', '1', '2', '3', '4', '5', 'ECDEPOS', 'Me senti descontento/a', '1', '2', '3', '4', '3', 'ECDEP41', 'Me senti desesperanzado/a', '1', '2', '3', '4', '5', 'Spanish (Universal)', '27 April 2012', 'o 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group']"
86,page_87,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '87', 'Version Date: 07/22/2019', 'PROMIS Item Bank V. 1.0 - Fatigue - Short Form 7a', 'Agotamiento - Cuestionario abreviado 7a', 'Responda a cada pregunta marcando una casilla por línea.', 'En los últimos 7 días', 'Algunas', 'Nunca', 'Rara vez', 'veces', 'A menudo', 'Siempre', 'FATEXP20', '¿ Con qué frecuencia se sintió cansado/a?', '1', '2', '3', '4', '5', 'i. Con qué frecuencia sintió extenuación', 'extrema?', '1', '2', '3', '4', '5', 'FATEXPS', 'FATEXP18', '¿Con qué frecuencia se quedó sin energía?', '1', '2', '3', '4', '5', 'Con qué frecuencia se vio limitado/a en el', 'trabajo debido al agotamiento (incluya el', 'FATIMP33', '1', '2', '3', '4', '5', 'trabajo en el hogar)?', 'Con qué frecuencia sintió demasiado', 'FATIMP30', 'cansancio como para pensar con claridad?', '1', '2', '3', '4', '5', 'Con que frecuencia sintió demasiado', 'FATIMP21', 'cansancio como para darse un baño o una', 'ducha?', '1', '2', '3', '4', '5', '¿. Con qué frecuencia tuvo suficiente energía', 'FATIMP40', 'como para hacer ejercicio vigoroso?', '5', '4', '3', '2', '1', 'Spanish (Universal)', '16 August 2012', 'o 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
87,page_88,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '88', 'Version Date: 07/22/2019', 'PROMIS Item Bank v.10 - Pain Interference - Short Form 6b', 'Efectos del dolor - Cuestionario abreviado 6b', 'Responda a cada pregunta marcando una casilla por línea.', 'En los últimos 7 días', 'Nada', 'Un poco', 'Algo', 'Mucho', 'Muchísimo', 'PAININ3', 'i En que medida el dolor interfirió en su', 'capacidad para disfrutar de la vida?', '1', '2', '3', '4', '5', 'PAININS', '¿', 'En qué medida el dolor interfirió en su', 'capacidad para concentrarse?', '1', '2', '3', '4', '5', 'PAINING', 'i En que medida el dolor interfirió en sus', 'actividades diarias?', '1', '2', '3', '4', '5', 'En qué medida el dolor interfirió en su', 'PAININ1O', 'capacidad para disfrutar de actividades', '1', '2', '3', '4', '5', 'recreativas o de ocio?', 'En qué medida el dolor interfirió en su', 'PAININ14', 'capacidad para realizar tareas fuera del hogar', '1', '2', '3', '4', '5', '(p. e]., hacer la compra o los mandados)?', 'En los últimos 7 días', 'Algunas', 'Nunca', 'Rara vez', 'veces', 'A menudo', 'Siempre', '¿Con qué frecuencia el dolor le impidió', 'PAININ26', 'socializar con otras personas?', '1', '2', '3', '4', '5', 'Spanish (Universal)', '12 September 2012', 'o 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 1']"
88,page_89,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '89', 'Version Date: 07/22/2019', 'PROMIS Item Bank v.1.0/1.1 - Global', 'Salud general', 'Responda a cada enunciado marcando una casilla por línea.', 'Muy', 'Excelente', 'buena', 'Buena', 'Pasable', 'Mala', 'Global01', 'En general, diría que su salud es', '5', '4', '3', '2', '1', 'Global03', 'En general, diría que su calidad de vida es', '5', '4', '3', '2', '1', 'GlobalDG', 'En general, ¿cómo calificaría su salud física?', '5', '4', '3', '2', '1', 'En general, ¿cómo calificaría su salud mental,', 'Global04', 'incluidos su estado de ánimo y su capacidad para', '5', '4', '3', '2', '1', 'pensar?', 'En general, ¿cómo calificaría su satisfacción con', 'Globalds', 'sus actividades sociales y sus relaciones con', '5', '4', '3', '2', '1', 'otras personas?', 'En general, califique en que medida puede', 'realizar sus actividades sociales y funciones', 'habituales. (Esto comprende las actividades en', 'casa, en el trabajo y en el área donde reside, así', '5', '4', '3', '2', '1', 'Global09', 'como sus responsabilidades como padre o madre,', 'hijo/a, cónyuge, empleado/a, amigo/a, etc.)', 'Completa-', 'En su', 'Moderada-', 'mente', 'mavoria', 'mente', 'Un poco', 'Para nada', '¿ En que medida puede realizar sus actividades', 'Global06', 'físicas diarias, como caminar, subir escaleras,', '5', '4', '3', '2', '1', 'cargar las compras o mover una silla?', 'Spanish (Universal)', '15 Feb 2012', 'o 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group', 'Page 1 of 2']"
89,page_90,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '90', 'Version Date: 07/22/2019', '16.4 APPENDIX IV: THE DISTRESS AND SYMPTOM CHECKLIST: THE DISTRESS', 'THERMOMETER', 'DISTRESS RATING TOOL', 'Patient', 'NAME:', 'DOB:', 'DATE:', 'INSTRUCTIONS: We know that all people can get sad and stressed out from time to time.', 'Sometimes people can get overwhelmed and distressed by managing all the aspects of their own life', 'along with their illness. When we say distress, we are referring to a range of feelings that can include', 'sadness, being anxious, fearful, worried, or upset. These feelings may affect how you feel physically', 'and emotionally.', 'On the thermometer below, circle the number that best describes how much distress you have', 'been feeling IN THE PAST MONTH with a ""0"" indicating no distress at all and a ""10"" indicating', 'the most distress you could possibly feel. Then, after indicating the level of distress on the', 'thermometer, please check the causes of YOUR distress.', 'Practical', 'Emotional', 'Have you been stressed about:', 'Have you been:', 'Not understanding what is', 'Worried/Anxious', 'happening to my body', 'Sad/Depressed', 'School work, work', 'Lonely/Feeling Alone', 'High Distress 10', 'Guilt/self-doubt', 'Taking a lot of medications', 'All my medical needs', 'Bored', '9', 'Doctor/hospital visits', 'Irritable', '8', 'Future plans- job/career', 'Afraid to be alone', 'Not having good friends', '7', 'Hopeless', 'Other Problems:', 'Difficulty making decisions', '6', 'Worthless', 'Moderate Distress', '5', 'Unhappy with how your body', 'looks (If so, what part', ')', '4', 'Having trouble concentrating', '3', 'Having racing thoughts', 'Spiritual', 'Scared (of', ')', '2', 'Have you been stressed about:', 'Angry', 'Spiritual Questions', '1', 'Other Problems:', 'Difficulties Praying', 'No Distress', '0', 'Feeling Distanced from God', 'Loss of Faith', 'Physical', 'Other Problems:', 'Have you been having problems with:', 'Pain', 'Getting around', 'Fatigue/lack of energy', 'Too much energy', 'Family/Social', 'Sleeping through the night', 'Have you been stressed about:', 'My weight(too high/too low)', 'Getting along with family', 'Eating too much, too little', 'Not having support', 'Headaches', 'Getting along with friends', 'Hair loss', 'Lack of communication', 'Heart palpitations', 'w/friends and family', 'Trouble with my vision, eyes', 'My parent(s) stress', 'Stomach aches/pain', 'My sibling(s) stress', 'Diarrhea/constipation (bowels)', 'Parent(s) being', 'Not able to exercise', 'overprotective', 'Other Problems:', 'Other problems:']"
90,page_91,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '91', 'Version Date: 07/22/2019', 'DISTRESS RATING TOOL', 'Caregiver', 'NAME:', 'RELATIONSHIP TO CHILD:', 'DATE:', 'INSTRUCTIONS: We know that people with a medical illness can get sad and stressed out from', 'time to time. Sometimes people can get overwhelmed and distressed by managing all the aspects of', 'their own life along with their illness. When we say distress, we are referring to a range of feelings', 'that can include sadness, being anxious, fearful, worried, or upset. These feelings may affect how you', 'feel physically and emotionally.', 'On the thermometer below, circle the number that best describes how much distress YOUR child', 'has been feeling IN THE PAST MONTH with a ""0"" indicating no distress at all and a ""10""', 'indicating the most distress he/she could possibly feel. Then, after indicating the level of distress', ""on the thermometer, please check the causes of YOUR CHILD'S distress."", 'Practical', 'Emotional', 'Has your child been stressed about:', 'Has your child been feeling:', 'Not understanding what is', 'Worried/Anxious', 'happening to his/her body', 'Sad/Depressed', 'School work, work', 'Lonely/Feeling Alone', 'Taking a lot of medications', 'Hiah Distress', '10', 'Guilt/self-doubt', 'Medical needs', 'Bored', 'Doctor/hospital visits', '9', 'Irritable', 'Future plans job/career', '8', 'Afraid to be alone', 'Not having good friends', 'Hopeless', 'Other Problems:', '7', 'Difficulty making decisions', '6', 'Worthless', 'Moderate Distress', 'Unhappy with how his/her', '5', 'body looks (What part', ')', '4', 'Having trouble concentrating', '3', 'Having racing thoughts', 'Spiritual', 'Scared (of', ')', 'Has your child been stressed about:', '2', 'Angry', 'Spiritual Questions', 'Other Problems:', '1', 'Difficulties Praying', 'Feeling Distanced from God', 'No Distress', 'o', 'Loss of Faith', 'Other Problems:', 'Physical', 'Has your child had problems with:', 'Pain', 'Getting around', 'Fatigue/lack of energy', 'Family/Social', 'Too much energy', 'Has your child been stressed about:', 'Sleeping through the night', 'Getting along with family', 'Weight(too high/toc low)', 'Not having support', 'Eating too much, too little', 'Getting along with friends', 'Headaches', 'Lack of communication', 'Trouble with his/her vision', 'w/friends/family', 'Stomach aches/pain', ""Parent's stress"", 'Diarrhea/constipation (bowels)', 'Sibling(s) stress', 'Not able/willing to exercise', 'Parent(s) being overprotective', 'Other Problems:', 'Other Problems:']"
91,page_92,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '92', 'Version Date: 07/22/2019', '17 REFERENCES', '1.', 'Boikos SA, Pappo AS, Killian JK, et al. Molecular Subtypes of KIT/PDGFRA Wild-', 'Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health', 'Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016.', '2.', 'Kelly L, Bryan K, Kim SY, et al. Post-transcriptional dysregulation by miRNAs is', 'implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]. PLoS One', '2013;8:e64102.', '3.', 'Favier J, Briere JJ, Strompf L, et al. Hereditary paraganglioma/pheochromocytoma and', 'inherited succinate dehydrogenase deficiency. Horm Res 2005;63:171-9.', '4.', 'Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the', 'spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal ce ll', 'cancer. J Med Genet 2006;43:18-27.', '5.', 'Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J', 'Nephrol Renovasc Dis 2014;7:253-60.', '6.', 'Waterfall JJ, Killian JK, Meltzer PS. The role of mutation of metabolism-related genes in', 'genomic hypermethylation. Biochem Biophys Res Commun 2014;455:16-23.', '7.', 'Letouze E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator', 'phenotype in paraganglioma. Cancer Cell 2013;23:739-52.', '8.', 'Xiao M, Yang H, Xu W, et al. Inhibition of alpha-KG-dependent histone and DNA', 'demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH', 'tumor suppressors. Genes Dev 2012;26:1326-38.', '9.', 'Reichardt P, Joensuu H, Blay JY. New fronts in the adjuvant treatment of GIST. Cancer', 'Chemother Pharmacol 2013;72:715-23.', '10.', 'Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in', 'gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A', '2011;108:314-8.', '11.', 'Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit', 'SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J', 'Hum Genet 2001;69:49-54.', '12.', 'Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics,', 'management, and treatment. Curr Probl Cancer 2014;38:7-41.', '13.', 'Kantorovich V, King KS, Pacak K. SDH-related pheochromocytoma and paraganglioma.', 'Best Pract Res Clin Endocrinol Metab 2010;24:415-24.', '14.', 'Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma', 'syndrome associated with mutations of the SDHC gene. JAMA 2005;294:2057-63.', '15.', 'Richter S, Klink B, Nacke B, et al. Epigenetic Mutation of the Succinate Dehydrogenase', 'C Promoter in a Patient With Two Paragangliomas. J Clin Endocrinol Metab 2016;101:359-63.']"
92,page_93,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '93', 'Version Date: 07/22/2019', '16.', 'Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a', 'novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014;21:567-77.', '17.', 'Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma effective', 'treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern', 'Med 1988;109:267-73.', '18.', 'Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination', 'chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant', 'pheochromocytoma and paraganglioma. Horm Cancer 2013;4:103-10.', '19.', 'Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy', 'with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and', 'pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 2014;81:642-', '51.', '20.', 'Fishbein L. Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment.', 'Hematol Oncol Clin North Am 2016;30:135-50.', '21.', 'Yoshinaga K, Oriuchi N, Wakabayashi H, et al. Effects and safety of (1)(3)(1)I-', 'metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results', 'from a multicenter observational registry. Endocr J 2014;61:1171-80', '22.', 'Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell', 'cancer (HLRCC): renal cancerrisk surveillance and treatment. Fam Cancer 2014;13:637-44.', '23.', 'pharmaceuticals A. SGI-110 Investigator Brochure version number 5.0. 2014.', '24.', 'Network DTNCC.http://www.nccn.org/about/news/newsinfo.asp?News ID=47', '25.', 'Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psychologic distress in', 'ambulatory cancer patients. Cancer 05;103:1494-502.', '26.', 'Ransom S, Jacobsen PB, Booth-Jones M. Validation of the Distress Thermometer with', 'bone marrow transplant patients. Psycho-oncology 2006; 15:604-12.', '27.', ""Zwahlen D, Hagenbuch N, Carley MI, Recklitis CJ, Buchi S. Screening cancer patients'"", 'families with the distress thermometer (DT): a validation study. Psycho-oncology 2008;17:959-', '66.', '28.', 'Patel SK, Mullins W, Turk A, Dekel N, Kinjo C, Sato JK. Distress screening, rater', 'agreement, and services in pediatric oncology. Psycho-oncology 2011;20:1324-33.', '29.', 'Wiener L ZS, Battles H, Pao M. Can an Adapted Distress Thermometer in the Pediatric', 'Population be Valid and Clinically Meaningful? Psycho-oncology 2012;21.', '30.', 'Cella D, Gershon R, Lai JS, Choi S. The future of outcomes measurement: item banking,', 'tailored short-forms, and computerized adaptive assessment. Quality of life research : an', 'international journal of quality of life aspects of treatment, care and rehabilitation 2007;16 Suppl', '1:133-41.', '31.', 'Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement', 'Information System (PROMIS) developed and tested its first wave of adult self-reported health', 'outcome item banks: 2005-2008. Journal of clinical epidemiology 2010;63:1179-94.']"
93,page_94,"['Abbreviated Title: Ph II SGI110 in Peds & Adults', '94', 'Version Date: 07/22/2019', '32.', 'Varni JW, Stucky BD, Thissen D, et al. PROMIS Pediatric Pain Interference Scale: an', 'item response theory analysis of the pediatric pain item bank. The journal of pain : official', 'journal of the American Pain Society 2010;11:1109-19.', '33.', 'Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate', 'dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA', 'germline mutation. Am J Surg Pathol 2013;37:234-40.', '34.', 'Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and', 'other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential', 'diagnosis. Mod Pathol 2012;25:854-8', '35.', 'Saxena N, Maio N, Crooks DR, et al. SDHB-Deficient Cancers: The Role of Mutations', 'That Impair Iron Sulfur Cluster Delivery. J Natl Cancer Inst 2015;10', '36.', 'Aspuria PJ, Lunt SY, Varemo L, et al. Succinate dehydrogenase inhibition leads to', 'epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab', '2014;2:21.', '37.', 'Lombardi G, Corona G, Bellu L, et al. Diagnostic value of plasma and urinary 2-', 'hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. Oncologist', '2015;20:562-7.', '38.', 'Liesenfeld DB, Botma A, Habermann N, et al. Aspirin Reduces Plasma Concentrations of', 'the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover', 'Trial. Cancer Epidemiol Biomarkers Prev 2016;25:180-7.', '39.', 'Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for', 'estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic', 'Acids Res 2004;32:e38.', '40.', 'Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials', '1989;10:1-10.']"
